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The kynurenine pathway is the prime pathway for the metabolism of the essential 
amino acid, tryptophan (TRP), and also the de novo pathway for nicotinamide adenine 
dinucleotide (NAD+) production. The kynurenine pathway is important in the 
pathogenesis of multi-organ dysfunction syndrome following severe acute pancreatitis 
(AP-MODS) due to the metabolism of kynurenine (KYN) into cytotoxic 3-
hydroxykynurenine (3HK) by the enzyme kynurenine 3-monooxygenase (KMO). 
Mice with absent Kmo gene expression (KMOnull) have marked reductions in 
extrapancreatic organ injury post AP.  
This dissertation describes the pharmacokinetics (PK) of the kynurenine pathway after 
intravenous infusion of deuterated or heavy carbon stable isotopes (tracers) of four 
kynurenine pathway compounds (D5-TRP, 13C6-KYN, D5-kynurenic acid (KYNA) 
and 13C6-3HK) into rats (n=13). 
Liquid chromatography-electrospray ionisation tandem mass spectrometry (LC-
MS/MS) is the most frequently used method to monitor kynurenine pathway 
compound levels in plasma. This dissertation reports a new method of extraction of 
plasma samples, using solid phase extraction (SPE), alongside improvement and 
optimisation of existing LC-MS/MS protocols using a reverse phase ultra-high 
performance C18-pentafluorophenyl column. This has enabled the analysis of each 
main metabolite in the kynurenine pathway in a single assay. Mass spectra of 
compounds were detected using electrospray ionisation (ESI) in both positive and 
negative polarity employing multiple reaction monitoring (MRM) modes over a 9 min 
total run time with an injection volume of 10 µL and flow rate of 0.4 mL/min. The 
method for each compound was shown to be reproducible and accurate (RSD < 25%) 
and each corresponding standard curve demonstrated linearity (R2 >0.99). 
Single compartment temporal PK analysis of tracers in rat plasma, during the 
elimination phase, reveals short mean half-lives for each compound, suggesting that 
metabolism through the kynurenine pathway is rapid (t1/2 12.14 – 29.12 mins). There 
was a marked difference in the volume of distribution of each analyte (D5 KYNA 0.12; 
13C6-3HK 0.21; 13C6-KYN 0.96 and D5-TRP 0.92 (µg/kg)/(µg/L)). Enzyme rates of 




In conclusion, a new accurate and reliable LC-MS/MS method for the analysis of 
kynurenine pathway metabolites has been developed. PK analysis has identified 
important and significant differences in the apparent volumes of distribution of each 
metabolite. Thus, it can be suggested that TRP and KYN are readily distributed to 






It	 is	 present	 in	 the	 diet.	 However,	 it	 is	 known	 that	 some	 breakdown	 products	 of	
tryptophan,	formed	in	the	body,	can	be	toxic	to	cells	and	be	related	to	several	severe	
disease	conditions.	Blocking	these	breakdown	products	could	be	a	means	to	treating	
these	 severe	 diseases.	 This	 study	 measured	 the	 levels	 of	tryptophan	 breakdown	
products	and	their	 length	of	 life	 in	blood	 in	the	healthy	animal.	To	accurately	and	
reliably	measure	these	breakdown	products,	it	was	also	necessary	to	develop	a	new,	
sophisticated	 assay	method.	 Thus,	 this	 study	 adds	 to	 the	 understanding	 of	 these	
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Tryptophan metabolism via the kynurenine pathway is a fundamental biological 
process that has generated increasing levels of attention in recent years. The pathway 
is likely to be involved in a range of diseases, including tumour immune resistance, 
neurodegeneration and multiple organ failure secondary to acute pancreatitis (Chen 
& Guillemin, 2009; Mole et al., 2008; Mole et al., 2016; Uyttenhove et al., 2003).  
 
1.1 Introduction to Tryptophan  
	
Tryptophan (TRP) is one of the nine essential amino acids that cannot be synthesised 
by mammals, therefore all TRP is acquired through the diet. TRP accounts for just 
one per cent of the recommended daily intake of essential amino acids 
(WHO/FAO/UNU, 2007), yet it serves as a precursor in the manufacture of several 
important biologically active metabolites including melatonin, serotonin and 
kynurenines (de Jong et al., 2009). TRP is the end product of a biosynthesis pathway 
involving the common precursor chorismate (Figure 1.1), a biochemical important in 
the formulation of many alkaloids, indoles, vitamin K, folate and amino acids, 
including phenylalanine and tyrosine. These, together with TRP, are important 
precursors to the production of neurotransmitters. The shikimate pathway that 
provides chorismate is not present in animals, thus chorismate has to be obtained 
from the diet. The synthesis of TRP consumes a vast amount of energy, requiring 
products of other pathways to provide essential carbons and nitrogens, these products 
include L-glutamine, the universal donor of amines, adenosine triphosphate (ATP), 
erythrose-4-phosphate, phosphoribopyrophosphate (PRPP) and L-serine, thus the 
formation of TRP can be seen as biologically expensive (Yanofsky, 2007). It has 
been suggested that the ability for mammalian cells to produce TRP was lost because 
of the biologically costly process of TRP formation. This, together with the 
abundance of TRP in the diet, led to a lack of evolutionary pressure to preserve the 
genes needed to produce TRP in animals. Conversely, in prokaryotes and eukaryotes, 






(Figure 1.1 - The Tryptophan Biosynthetic Pathway. The pivotal precursor to the 
production of aromatic amino acids is chorismate, a product of the shikimate pathway 
which is not present in animals. Chorismate is catalysed by anthranilate synthase 
using glutamine to produce anthranilate, glutamate and pyruvate. In many 
eukaryotes, mainly fungi, this enzyme is part of a multifunctional protein complex, 
divided into two subunits α and β. For instance in Neurospora Crassa, subunit β is 
encoded by the gene for phosphoribosylanthranilate isomerase (TRP1) which 
provides the active sites for reactions 3 and 4 (in red). The α subunit is encoded by 
TRP2 (anthranilate synthase) and provides the active site for reaction 1 when 
combined with subunit β provides the site for glutamine binding to catalyse 
anthranilate synthesis. The other two enzymes involved in this pathway are 





Table 1.1 - Genetic profile of enzymes involved in TRP biosynthesis (PUBMED) 
Gene Enzyme Encoded Function Lineage 
TRP1 Phosphoribosylanthranilate 
isomerase 









TRP2 Anthranilate Synthase Catalyses step 1 of TRP biosynthesis; 
Forms enzyme complex with indole-3-glycerol-phosphate 
synthase 
TRP3 Anthranilate synthase/ indole-
3-glycerol-phosphate synthase 
Contribute to Anthranilate synthase and indole-3-glycerol-
phosphate synthase activity  
Catalyses steps 1 and 4 in biosynthesis of TRP 
TRP4 Anthranilate 
phosphoribosyltransferase 
Catalyses step 2 in biosynthesis of TRP  
TRP5 Tryptophan synthase Catalyses step 5 in biosynthesis of TRP  
 
trpA Tryptophan synthase (α 
subunit) 
Involved in step 5 of TRP biosynthesis 
α subunit catalyses the cleavage of indole-3-glycerol-
phosphate to indole and d-glyceraldehyde 3-phosphate. It then 







trpB Tryptophan synthase (β 
subunit) 
Involved in step 5 of TRP biosynthesis.  
β subunit catalyses the pyridoxal 5’-phosphate-dependent 




anthranilate isomerase  
Catalyses the conversion of PR anthranilate to CdRP and also 
the ring closure of CdRP to IGP (reactions 3 and 4)  
 
trpD Component II of anthranilate 
synthase/anthranilate 
phosphoribosyltransferase 
Catalyses 2nd step of TRP biosynthesis 
Component II of anthranilate synthase is a glutamine 
amidotransferase aiding in step 1 of TRP biosynthesis. 
In E.coli this component also contains phosphoribosyl-
anthranilate transferase – further catalysing step 2 of TRP 
biosynthetic pathway by adding PRPP to anthranilate.   
trpE Component I of anthranilate 
synthase  
Catalyses 1st step of TRP biosynthesis by catalysing the 
formation of anthranilate using chorismate and ammonia. Also 











trpG Component II of anthranilate 
synthase 
Combines with trpE to catalyse the formation of anthranilate 
and glutamate from chorismate and glutamine. Provides the 
activity of glutamine amidotransferase.  
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1.1.1  The Structure of Tryptophan 
 
The structure of TRP consists of an indole ring, a five-membered ring with nitrogen 
bonded to a benzene ring, an α-carboxylic group and an amino group (Figure 1.2).  
a)                       b)  
(Figure 1.2 – a) The Structure of Tryptophan b) The Structure of the Indole Ring – 
the aromatic compound, indole, consists of a six-membered benzene ring fused with 
a five-membered, nitrogen-containing pyrrole ring at positions 2,3 on the pyrrole 
ring.)  
 
The presence of the indole ring allows tryptophan to bind to albumin through its 
indole-benzodiazepine site (Sudlow site II) (Conrad et al. 2009) with high affinity at 
physiological serum pH levels (McMenamy, 1965), therefore enabling TRP to be 
transported through the circulation bound to albumin (90%). The remainder (10%) is 
bioavailable in its free form in the resting state. The indole ring provides the basis to 
animal derivatives such as serotonin and melatonin. Other derivatives of indole have 
multiple biological actions. For example 2,3-diaryl-subsituted indoles possess anti-
inflammatory and analgesic properties mediated by cyclooxygenase-2 (COX-2) 
inhibition (Kalgutkar et al., 2005; Laube et al., 2014).  
The TRP-albumin interaction is of major importance to the pharmacokinetic and 
pharmacodynamic profile of TRP (Yamasaki et al., 2013).  This interaction provides 
a variety of functions, it stops the passive diffusion of the amino acid out of the 
circulation and through the endothelium of tissues or the blood brain barrier (BBB), 
prevents metabolism, excretion and action with therapeutic targets (Koch-Weser & 
Sellers, 1976). At physiological resting state, the ratio of albumin-bound to free TRP 
is in equilibrium (McMenamy, 1965). Because the binding of TRP to albumin is 
readily reversible, albumin can act as a reservoir for TRP, enabling the release and 
replenishment of the TRP pool when biotransformation of the amino acid is 
upregulated. It has been reported that this ratio can change significantly during 
different physiological states.  For instance, free TRP levels can be affected by the 
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serum concentration of non-esterified fatty acids (NEFAs) (Fernstrom & Fernstrom, 
2006; Ruddick et al., 2006), the presence of benzodiazepines (Muller & Wollert, 
1975) and the lipid-lowering agent clofibrate (Spano et al., 1974). NEFAs displace 
TRP from the Sudlow site II binding site, elevating the concentration of free TRP in 
the circulation. This phenomenon is reportedly seen in multiple physiological states, 
for instance during intense exercise training (Bassami et al., 2007), activation of the 
sympathetic nervous system (Dunn & Welch, 1991), and possibly in the obese (Karpe 
et al., 2011). This elevation in serum TRP subsequently results in elevated tissue 
levels, upregulating TRP metabolism.  
 
1.1.2  Metabolism of Tryptophan 
	
TRP is metabolised via several pathways including bacterial degradation in the 
gastrointestinal tract, serotonin production and subsequent melatonin production in 
the pineal gland, protein synthesis and the kynurenine pathway (Keszthelyi et al.,  
2009). This dissertation will focus on the kynurenine pathway. 
 
1.2 The Kynurenine Pathway 
	
It is estimated that up to 99% of the metabolism of dietary tryptophan is metabolised 
via the kynurenine pathway (Fig 5) (Stone & Darlington, 2002) (Keszthelyi et al., 
2009), with the remaining 1% being converted into serotonin. This generates a set of 
biologically active indole-derived metabolites, termed ‘kynurenines’.  
  
1.2.1  The Kynurenines 
	
The kynurenine pathway culminates in the production of NAD+, which is a 
fundamental component to metabolic processes occurring in all cells. These 
processes include the Krebs cycle, glycolysis, transcription and deoxyribonucleic 
acid (DNA) repair (Lin & Guarente, 2003). The kynurenine pathway metabolite that 
is the main precursor for NAD+ production is quinolinic acid (QUIN). 
 
TRP is initially metabolised by indoleamine 2,3-dioxygenase (IDO) and tryptophan 
2,3-dioxygenase (TDO). Formylkynurenine is then rapidly, non-enzymatically, 
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converted into kynurenine (KYN). Although KYN is an intermediate metabolite, 
there have been suggestions that it also exerts powerful actions itself, with one study 
identifying a role for KYN in stimulating the expression of nerve growth factor in 
cholinergic neurons (Dong-Ruyl et al., 1998). KYN is also present in high quantities 
within human eye lenses acting as a filter of ultraviolet (UV) light (Vazquez et al., 
2002), and has been linked to the formation of cataracts via UV irradiation (Varma 
& Hegde, 2010). KYN provides the substrate to three different enzymes producing 
different metabolites that exert diverse physiological effects. KMO converts KYN 
into the toxic 3-hydroxykynurenine (3HK); Kynurenine aminotransferase (KAT) 
converts KYN into KYNA which is neuroprotective, by virtue of being an antagonist 
at the N-methyl-D-aspartate (NMDA) receptor and competitive antagonist of QUIN 
(Boegman, et al., 1985; Guillemin et al., 2001) (Figure 1.3). Anthranilic acid is 
produced from KYN by kynureninase (Mandi & Vecsei, 2012; Vecsei et al., 2013). 
It is the creation of these toxic and neuroactive metabolites that has generated the 
present interest in the kynurenine pathway, as these metabolites have fundamental 
roles in inflammation, immunity and the pathogenesis of neurological disorders 





(Figure 1.3 – Diagram of the Kynurenine Pathway The main enzyme of interest 
is KMO (highlighted). This converts KYN into 3HK, a cytotoxic compound, which 
is then further metabolised into 3-hydroxyanthranilic acid (3HAA) by kynureninase 
(KYNU) and then into QUIN, a key compound in the de novo synthesis of NAD+. 
KYNU also metabolises KYN into anthranilic acid (AA) which then hydroxylates 













1.2.1.1  3-Hydroxykynurenine 
	
The production of 3HK by KMO is the predominant route of KYN metabolism 
(Lugo-Huitron et al., 2013). 3HK is further metabolised into 3-hydroxyanthranilic 
acid (3HAA) by kynureninase and through subsequent reactions to eventually form 
the coenzyme NAD+. Alternatively, 3HK can be metabolised by KAT to form XA, a 
free radical scavenger (Schwarcz et al., 2012).  
3HK is a cytotoxic metabolite that exerts oxidative damage and induces cell death, 
thus contributing to the pathogenesis of tissue injury and neurodegenerative 
conditions (Colin-Gonzalez et al., 2013). The oxidation of 3HK is readily catalyzed 
by copper (Cu2+) and iron (Fe3+) in physiological conditions to generate the reactive 
oxygen species (ROS), hydrogen peroxide (H2O2) and superoxide (O2-). ROS are 
powerful inducers of oxidative stress and thus contribute to inflammation, 
endothelial dysfunction, cellular apoptosis and tissue damage (Coyle & Kader, 2007; 
Goldstein et al., 2000). This auto-oxidation process is believed to be the main 
mechanism behind 3HK-driven neurotoxicity rather than acting on specific receptors 
(Thevandavakkam et al., 2010). Experimental medical studies have shown that levels 
of 3HK are increased in neurological pathologies such as Huntington’s disease 
(Thevandavakkam et al., 2010), Parkinson’s disease (Colin-Gonzalez et al., 2013; 
Okuda et al., 1998) and pneumococcal meningitis. However, some studies have 
identified 3HK to be a scavenger of free radicals and potentially acting as an 
antioxidant (Christen et al., 1990; Goshima et al, 1986; Leipnitz et al., 2007). It has 
been proposed that these anti-oxidant effects occur at natural physiological 
concentrations and the oxidative stress properties at high concentrations (Colin-
Gonzalez et al., 2013). Alternatively, 3HK may potentiate the effects of another toxic 
metabolite of the kynurenine pathway, QUIN, and the two together may form the 
underlying cause of neurotoxicity (Guidetti & Schwarcz, 1999). 
More recently, 3HK has been proposed as the driver of systemic inflammation, and 
subsequent multi organ dysfunction following tissue injury due to trauma, acute 
pancreatitis, chronic renal failure and sepsis (Mole et al., 2016). This gives rise to the 
concept that KMO is the fundamental gate-keeper enzyme which by determining the 




1.2.1.2  Quinolinic Acid 
	
QUIN is formed via the incorporation of O2 into 3-hydroxyanthranilic acid (3HAA) 
by 3-hydroxyanthranilate 3,4-dioxygenase (3HAO), this initially produces the 
unstable 2-amino-3-carboxymuconate semialdehyde which spontaneously converts 
to QUIN (Foster et al., 1986).  This metabolite provides the substrate for 
NAD+ production by quinolinic acid phosphoribosyltransferase (QPRT) (Foster et 
al., 1985). In situations of inflammation, QUIN production in macrophages is very 
much reliant on the induction of IDO via interleukins and cytokines such as 
interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) (Guillemin, 2012).  
QUIN can be metabolised peripherally and in the central nervous system (CNS) 
(Lugo-Huitron et al., 2013). However, studies have established that QUIN cannot 
cross the BBB, and therefore QUIN metabolism in the periphery and CNS are 
independent (Foster et al., 1984; Lugo-Huitron et al., 2013). Kohler et al. identified 
that the cells with the greatest abundance of QPRT in rat brains are glial cells (Kohler, 
et al., 1987) and the highest reported activity is located in the olfactory bulb (Foster 
et al., 1985). However, QPRT is present in considerably lower quantities in 
comparison with 3HAO. This results in a Michaelis binding constant (KM), that is 80 
times less than that of 3HAO, leading to an accumulation of QUIN in conditions 
where the kynurenine pathway is upregulated (Foster et al., 1986). As QUIN is a 
neurotoxin when present in excess, this upsurge may be pathologically important in 
neurological disease states (Lugo-Huitron et al., 2013), for example Alzheimer’s 
disease, Parkinson’s disease, Huntington’s disease, motor neuron disease, multiple 
sclerosis, HIV-associated neurocognitive impairment and psychological 
dysregulation such as severe depression (Najjar et al., 2013).    
QUIN is a powerful glutamate agonist and therefore exerts an excitatory effect at the 
NMDA receptor located on human primary astrocytes (Lugo-Huitron et al., 2013), 
especially on the subgroup that contains the subunits GluN1 and GluN2A (Guillemin, 
2012). NMDA over-activation is regarded as a well-established process that elicits 
neurodegeneration (Vecsei et al., 2013). Over stimulation of NMDARs triggers an 
influx of Ca2+, elevating cytosolic Ca2+ concentrations (Akaike et al. 1999). This 
results in the upregulation of neuronal nitric oxide synthase (nNOS) and subsequent 
production of nitric oxide (NO). NO can react with superoxide to produce 
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peroxynitrite (ONOO-), a potent inducer of neuronal death (Lafon-Cazal et al., 1993; 
Santamaria et al., 2001). NMDAR-triggered Ca2+ influx also initiates iron-catalyzed 
production of hydroxyl free radicals (.OH) and induces lipid peroxidation, thereby 
provoking DNA fragmentation, altering cell membrane fluidity and ion permeability 
resulting in neuronal dysfunction (Santamaria et al., 2001). Therefore, QUIN-
mediated Ca2+ influx can result in astrocyte death (Guillemin, 2012).  
Santamaria et al. investigated the role of QUIN in oxidative stress by incubating rat 
synaptosomes with varying concentrations of QUIN. In support of previous findings 
(Rios & Santamaria, 1991), these experiments exhibited a concentration-dependent 
rise in lipid peroxidation-related ROS formation, which was dampened by 
administration of glutamate receptor antagonists (Santamaria et al., 2001). QUIN-
mediated neurotoxicity has also been reported to be completely eradicated by the 
administration of MK-801, an NMDAR antagonist (Frumento et al., 2002).  This 
reversal of lipid peroxidation therefore gives scope to further research that aims to 
investigate and identify potential enzymes that can be targeted to directly reduce the 




1.2.1.3  Kynurenic Acid 
	
Kynurenic Acid (KYNA), is a NMDAR antagonist, and therefore protects against 
neuronal excitotoxicity by glutamate-derived excitotoxins and QUIN. KYNA also 
exerts non-competitive inhibition on nicotinic acetylcholine receptors (nAChRs), in 
particular α7nAChR.  α7nAChR inhibition decreases extracellular GABA levels, 
thus affecting the inhibitory neuronal network (Beggiato et al., 2014). As a 
consequence, compromised α7nAChR activity and KYNA are implicated in multiple 
neurological disorders, for example schizophrenia and Huntington’s, diseases in 
which GABA dysregulation features prominently in the pathogenesis (Wassef et al., 
2003; Yamamura et al., 1980).  
Following the reporting by Lapin of a reduction in the severity of QUIN-induced 
seizures after KYNA administration (Lapin, 1976),  KYNA has been the subject of 
investigations exploring the potential as an anticonvulsant and in neuroprotection 
(Moroni et al., 2012; Stone, 2000). Foster et al. reported that KYNA blocks QUIN-
mediated seizures and neurotoxic damage in rats (Foster et al., 1984). In the brain, 
KYNA is produced mainly in glial cells via the catabolism of KYN by KATs (Figure 
1.4) and acts on a specific binding site within the NMDAR, namely the strychnine-
insensitive glycine-binding site (glycine allosteric site) (Szalardy et al., 2012). 
KYNA also exerts an inhibitory effect on acetylcholine-regulated pathways via 
presynaptic α7nAChRs, exerting anti-glutaminergic properties providing further 
protection from NMDA-mediated excitotoxicity and neurodegeneration (Vecsei et 
al., 2013). KYNA also effects the α-amino-3-hydroxi-5-metylisoxazol-4-propansyra 
(AMPA) receptor at high concentrations, and also has an effect on the G protein-
coupled receptor 35 (GPR35) (Wennstrom et al., 2014).  
The exact role of KYNA in neuroprotection is still debated as there are additional 
studies that can be construed as contradictory, including investigations into KYNA 
in Alzheimer’s disease. It has been reported that peripheral levels of KYNA are 
significantly reduced in plasma and red blood cells in patients who have Alzheimer’s 
(Hartai et al., 2007). Another group observed decreased levels in cerebrospinal fluid 
(CSF) (Baran et al., 1999). Together, these studies suggest that downregulation of 
KYNA may result in a loss of neuroprotection. This uncertainty has prompted recent 
investigations by Wennstrom et al. into the correlation between KYNA levels and 
13	
	
symptomatic Alzheimer’s patients, which have been inconclusive (Wennstrom et al., 
2014). Interestingly, pre-clinical studies, using transgenic mouse models of 
Alzheimer’s and Huntington’s disease which have used pharmacological inhibitors 
of KMO to increase KYNA levels have described a significant protection against 
neurodegeneration in these models (Zwilling et al., 2011). While these preclinical 
experiments show promise, and have potentiated interest and further research into 
drug development for KMO inhibition in neurodegenerative diseases (Reinhart & 
Kelly, 2011), they are complicated by the fact that the pro-drug of KMO used in these 
experiments, JM6, has been subsequently shown not to be converted to the active 
KMO inhibitor that was theoretically proposed (Beconi et al., 2012). 
Peripherally, KYNA plays an important role in the regulation of the immune system 
and in the oncogenesis of gastric cancer via selectively activating the G protein-
coupled receptor 35 (GPR35), a receptor present in immune and gastrointestinal cells 
(Chen & Guillemin, 2009; Wang et al., 2006). Heightened levels of KYNA during 
inflammation reduce TNFα levels, induced by lipopolysaccharide (LPS), providing 




1.2.2  Kynurenine 3-Monoxygenase  
	
Kynurenine 3-monoxygenase (KMO), also known as kynurenine 3-hydroxylase, is a 
flavin adenine dinucleotide (FAD)-dependent, monomeric protein that is part of the 
external flavoprotein aromatic hydroxylase family (Breton et al., 2000).  KMO 
consists of 486 amino acids and has a molecular mass of ≈55.8 kDa when in its 
dissociated form, located on the outer membrane of mitochondria (Alberati-Giani et 
al., 1997; Crozier & Moran, 2007; Okamoto et al., 1967; Uemura & Hirai, 1998) in 
macrophages and microglia (Wilson et al., 2014). The KMO gene is located on 1q42-
q44 (Wonodi et al., 2014).  KMO has a vital role in the kynurenine pathway. Its 
function is to catalyse the hydroxylation of KYN into the cytotoxic intermediate 3HK 
and water, using nicotinamide adenine dinucleotide phosphate (NADPH) as an 
electron donor, and one atom of oxygen (Figure 1.4) (Breton et al., 2000). Initiation 









(Figure 1.4 - The Proposed Hydroxylation of KYN by KMO.  KMO hydroxylates 
KYN resulting in the irreversible production of the toxic metabolite 3HK. The dotted 





1.2.2.1  The Structure of KMO 
	
The structure of KMO was identified in Saccharomyces cerevisiae in 2013 (Amaral 
et al., 2013) and has a 51% similarity to the human form. Human KMO crystal 
structure studies have been unsuccessful to date because the presence of a C-terminal 
transmembrane helix causes difficulties in purification (Wilkinson, 2013). FAD is 
tightly bound non-covalently and the reduction of FAD by cofactors NADPH or 
reduced NAD+ (NADH) is fundamental to the activity of KMO and the catalysis of 
KYN into 3HK (Breton et al., 2000; Smith et al., 2016). The Mole group has used 
the Pseudomonas fluorescens KMO (pfKMO) structure for drug design. The residues 
surrounding the binding pocket of KYN, are structurally conserved in humans. 
Therefore, with the exemption of HIS320 which is exchanged for phenylalanine in 
human KMO, the binding pocket of pf KMO is hypothesized to be identical to human 
KMO (Mole et al., 2016). 
PfKMO consists of three domains (Figure 1.5) all of which encapsulate a split 
hydrophobic and hydrophilic binding pocket. The first domain (domain 1) binds to 
FAD via a nucleotide protein structural motif, an N-terminal Rossmann-like fold 
consisting of five parallel β-strands. Two anti-parallel β-strands connect this domain 
with the second domain (domain 2) which is responsible for interacting with KYN.  




(Figure 1.5 - The Three Domains of KMO. An illustration representing the three 
domains of KMO, blue, red and purple respectively, bound to both FAD and KYN. 
Figure from (Wilkinson, 2013)) 
 
Inhibitors of KMO have been developed previously. Most were analogues of KYN 
(o-, m-, and p-nitrobenzoylalanine) but these were identified to have a role in 
NADPH oxidation, creating a peroxyflavin species that subsequently decays, 
generating hydrogen peroxide (Crozier-Reabe et al., 2008). Thus research has 
diverted from analogues of KYN to benzenesulphonamide scaffolds (Röver et al., 
1997), including Ro 61-8048, a potent competitive inhibitor of KMO . The latter has 




1.2.2.2  Distribution of KMO 
	
Distribution studies of KMO activity in rats have revealed that there is a modest, 
ubiquitous level of activity in the brain, whilst the highest levels of activity are found 
in the liver and kidney (Erickson et al., 1992). Further studies by the Mole group into 
Kmo mRNA expression in wild-type C57BL6 mouse tissue has shown high Kmo 
expression in liver and kidney, and moderate expression in secondary lymphoid 
tissue, including spleen, lung, mesenteric and peripheral lymph nodes Mole et al., 
2016) (Figure 1.6).   KMO activity is a key rate determinant of the downstream 
kynurenine pathway. Decreased KMO activity alters KYN concentrations through a 
buildup of substrate, increases KYNA through diversion of KYN metabolism, and 
decreases 3HK, 3HAA and QUIN (Crozier & Moran, 2007). This altered metabolic 
profile drastically changes the inflammatory and neurodegenerative landscape. KMO 
activity is upregulated in inflammatory states (Alberati-Giani et al., 1997) via IFN-











(Figure 1.6 – Kmo mRNA Expression in Tissue. KMO expression is predominant 
in liver and kidney tissue. KMO expression is also present in secondary lymphoid 
tissues such as mesenteric and peripheral lymph nodes. (Mean ± standard error of 
the mean; Kmo mRNA expression is relative to an 18S RNA internal control from 
kidney tissue extract from wild-type C57BL6 mice, which was assigned a value of 
















1.2.2.3  KMO Interactions with KYN 
	
The mechanism of KMO highlighted in Figure 1.4 is complex and is yet to be fully 
determined (Smith et al., 2016). The Mowat group at the University of Edinburgh 
has successfully crystalised a PfKMO-KYN co-structure and this can be used to 
model KYN’s interaction with KMO and FAD (Wilkinson, 2013). KYN interacts 
with the oxygen on the isoalloxazine ring of the noncovalently bound FAD in a 
hydrophobic pocket. This pocket is lined by residues Leu213, Ile215, Ile224, Leu226, 
Phe238 and Phe319. The carboxylate group sits in the hydrophilic pocket 
encapsulated by residues Arg84, Tyr98, His320, Asn369 and Tyr404 whilst 





(Figure 1.7 - The KMO Binding Pocket. The FAD and KYN binding domains. 
Proposed bonds are displayed and main KMO residues highlighted. Enzyme residues 
(grey), KYN and FAD (cyan). Heteroatoms are coloured as: Sulphur (yellow); 





1.2.2.4  The Role of KMO in Pathology 
 
1.2.2.4.1  Neurodegeneration  
	
KMO is predominantly expressed in microglial cells in the brain, however general 
expression in the brain is low (Amaral et al., 2013). Inflammatory states induce the 
infiltration of macrophages into the brain, increasing levels of QUIN propagating 
toxic effects on neurons (Guillemin et al., 2003). QUIN injected directly into the 
brain, in particular the nucleus basalis, creates a glutamate receptor excitotoxic 
environment, reproducing the neurochemical alterations seen in Huntington’s 
Disease (HD) (Boegman et al., 1985) (Stoy et al., 2005). QUIN injections have 
therefore been used as a mouse model of HD (R. Schwarcz et al., 1983). QUIN 
administration has been reported to induce the expression of huntingtin, the gene 
responsible for the development of HD, adding further credence to the hypothesis 
that QUIN may play a role in the induction of HD (Tatter et al,. 1995). In contrast, 
Stoy et al. studied the possible role of the kynurenine pathway in HD patients, 
comparing peripheral serum samples with healthy volunteers. There were no 
differences in QUIN levels between patients and healthy volunteers despite an 
elevated KYN:TRP ratio in HD patients (Stoy et al., 2005). However, these authors 
acknowledged that peripheral serum concentrations may not be directly 
representative of the CNS environment. Raised 3HK levels have been observed in 
Parkinson’s disease (Ogawa et al., 1992), mouse models of Huntington’s disease 
(Guidetti et al., 2006), rat models of multiple sclerosis (Chiarugi et al., 2001)  and 
infantile spasms (Yamamoto et al., 1994). Open-approach “bottom up” 
metabolomics studies, have also identified an increase of 3HK in association with 










1.2.2.4.2  KMO in Systemic Inflammation and Acute Pancreatitis.  
	
KMO activity is important in systemic and local inflammation, in particular that 
resulting from acute pancreatitis (AP).  
The incidence of AP in the UK is reported to be between 15 and 42 per 100,000 
population. The incidence of AP is increasing, possibly due to increasing alcohol 
consumption (Ellis et al., 2009; Goldacre & Roberts, 2004; McKay et al., 1999; 
Phillip et al., 2014). The mortality rate of severe AP cases, despite the advances in 
intensive medical support and care ranges between 15-30% (Beckingham & 
Bornman, 2001; Gooszen et al., 2013). The proportion of AP deaths occurring in the 
first week of admission has remained between forty to sixty per cent. This is due to 
the high risk of developing multiple organ dysfunction syndrome (MODS) in the 
early stages of severe AP, which is normally the cause of death in these patients 
(McKay et al., 1999).  Since the 1970’s, there has been no progress in treatment with 
most therapies used to treat the symptoms rather than the disease itself (Phillip et al., 
2014). Therefore, it is important to understand in more detail the cellular and 
hormonal mechanisms that are induced during the disease. In particular, research has 
focused on the roles of the kynurenine pathway in modulating the transition between 
AP and AP-induced multi organ dysfunction syndrome (AP-MODS). 
In AP-MODS, the most commonly affected extra-pancreatic organ is the lung. 
Histological analysis of experimental AP Kmowt mice identified alveolar wall 
thickening, inflammatory cell infiltration and interstitial oedema (Mole et al., 2016).  
Acute kidney injury (AKI) also occurs in AP-MODS, with histological TUNEL 
analysis identifying marked cellular apoptosis in Kmowt kidney tissue. To identify 
whether KMO has a specific role in the pathogenesis and severity of AP-MODS, the 
Mole group created a strain of mice that is homozygous for Kmo knockout-first tm1α 
allele (Kmonull) that were unable to produce 3HK. The level of apoptosis seen in these 
mice was considerably lower and significant protection against acute lung and kidney 
injury was subsequently seen (Mole et al., 2016). This leads to the conclusion that 
KMO plays a key role in determining the progression of severe sterile inflammatory 
disease states into critical illness. (Mole et al., 2016). These findings were 
recapitulated using the novel KMO inhibitor GSK180 in an experimental rat model 
of AP. KMO inhibition can therefore protect against AP-MODS. 
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1.3 Pharmacokinetics and Pharmacodynamics 
	
Drug discovery and development requires an understanding of how a drug is 
absorbed, distributed, metabolised and eliminated (ADME/PK) from body systems, 
as well as an understanding how a drug effects these systems physiologically 
(pharmacodynamics, PD). PK/PD studies enable scientists and clinicians to 
understand the mechanisms of drug action, as well as identifying how a drug 
distributes across body compartments. Drugs can therefore be designed to achieve an 
optimal potency and desired effect at doses, which are therapeutic yet minimalise 
unwanted toxic side effects (Tuntland et al., 2014). The creation of a theoretical 
model of a drug’s action before development, based on preclinical and clinical data 
analysis, can aid simulation of multiple aspects of drug behaviour and forecast its 
success in trialing. This includes simulation of the efficacy of a drug in clinical 
scenarios, whilst also predicting the dose-response relationship (Miller et al., 2005). 
Successful modeling in early drug discovery can benefit numerous facets during 
development, not only by aiding selection of the compound with the greatest 
potential, but also by reducing costs of development, as well as animal use, and 
reducing development time (Tuntland et al., 2014). 
Despite research into the PK of TRP and the renal excretion of KYN during the 
1980’s (Moller, 1981), there has been little work since then to further develop and 
define the precise peripheral PK of TRP and its metabolites along the kynurenine 
pathway, especially of KYNA and 3HK. As the kynurenine pathway has been 
implicated in multiple disease states, it is important to understand the PK of the 
downstream kynurenine pathway metabolites and what proportions of metabolites 
become substrate for their corresponding enzymes and the rates of activity of these 
kynurenine pathway enzymes. These studies would allow the further modelling and 
simulation of the kynurenine pathway following KMO inhibition, identifying how 
KMO inhibitors affect the status quo of KYN metabolism thus uncovering the 
potential upstream and downstream consequences of this inhibition.  
 
 




1.3.1  Elimination Constant 
	
The elimination constant, kel, describes the exponential process that represents the 
rate at which a fraction of drug is removed from the body over a period of time. The 
removal of a drug is a dynamic process; normally dependent on the concentration of 
the drug. As the drug concentration reduces, the rate of change decelerates 
exponentially (Roberts & Freshwater-Turner, 2007). kel can be calculated using the 
equation in Table 1.3, it can also be identified using a semi-log plot of concentration 





(Figure 1.8 – Example of an Exponential Curve. A) The concentration of drug in 
plasma shows an exponential decline in levels over time. B) This can be plotted on a 
semi-log plot to give the gradient of decline (y= intersect•e-kel). This gradient can also 
be used to work out the initial concentration (Ci), where the trend-line crosses the y 





1.3.2  Volume of Distribution 
	
The volume of distribution (Vd) represents the hypothetical volume of plasma that is 
required to contain the total amount of drug administered at the concentration that is 
observed in the plasma (Cp). It can be used to establish the target dose of drug needed 
to achieve optimal initial concentrations (Ci) in the blood. Vd is calculated using the 
equation in Table 1.2.  
The value of the Vd for a drug represents the ability of the drug to readily be taken up 
by tissues. Values of Vd can appear to exceed that of normal body L/kg ratios. This 
is due to the ability of the drug to accumulate and concentrate in peripheral 
compartments such as fat and muscle, therefore reducing the circulating 
concentration.  It is a theoretical volume and does not actually have to represent an 
anatomical compartment. The higher the value of Vd, the greater the drug’s ability to 
distribute into tissues. Drugs with a low Vd are confined to the vascular compartment. 
This may occur for a variety of reasons: 1) due to the size of the drug and whether it 
can cross into cells; 2) whether the drug is highly polar or; 3) whether there is a high 
affinity for the drug to bind to plasma proteins such as albumin. There are a number 
of clinical implications arising from this. For example, only an unbound drug has the 
ability to exert its desired effects on the target. Therefore, binding to albumin reduces 
the drug potency and possibly the therapeutic efficacy.   
 
1.3.3  Half-Life and Steady State. 
	
The half-life (t1/2) represents the time taken for Cp to halve. It is inversely related to 
kel (Table 1.2), and therefore is governed by Vd and total clearance (CLtot). t1/2 is 
important clinically as it is used to determine the length of time it takes for a drug to 
accumulate to a therapeutic steady state level (four-five times t1/2). The longer the t1/2 
of a drug, the longer it will take to achieve steady state, thus a loading dose may be 
required to reach a steady state more rapidly. It is also important for therapeutic drug 
monitoring, especially when using drugs with a very narrow therapeutic window 




1.3.4  Clearance 
	
The collective elimination of a drug, over a unit of time, via hepatic metabolism 
(CLmet), renal excretion (CLren) and other routes of elimination (e.g. gaseous 
exchange and biliary excretion), (CLtot). By generating an AUC0-t between the bolus 
dose (Q, time point 0) and the last measured time point (t), !"#$# can be calculated 
(Table 1.2). !"#$# is an important parameter in PK as it aids calculation of the target 
therapeutic dose and the length of the therapeutic window. Clinically, changes to 
renal function, such as chronic kidney disease, will affect !"#$# and therefore drugs 
have to be dosed accordingly (Munar & Singh, 2007). CLtot can be used to calculate 
the rate of elimination (eq. 1) as well as kel.  
 
%&'(	*+	,-./	012324&'2*4 = !*46(4'-&'2*4	24	71&83&	(!:)	<	!"#$#	 à  
(Equation .1)  
 
Table 1.2 - PK Parameters and Their Corresponding Equations  
Parameter Symbol Units Equation  





































Dose , µg/kg  
Steady State Enzymatic 
turnover 










1.3.5  The Partition Coefficient, LogP 
	
The 1-octanol-water partitioning coefficient (P) represents the 
lipophilicity/hydrophobicity of a compound in solution at equilibrium. It defines the 
distribution of a compound between two immiscible phases, cytosol and lipid bilayer 
in cells. These two phases are represented by water and 1-octanol respectively, and 
therefore can be used to compare the ability of a compound to solubilise and 
distribute across biological membranes (Griffin et al., 1999). LogP is measured by 
mixing a compound in a solution of water and 1-octanol, allowing the two phases to 
separate, then measuring and comparing the concentrations of the compound in each 
phase (Bowman & Sans, 1983). The difference between the two concentrations, P, 
can be assessed on a logarithmic scale (LogP, eq.2). Low Log P values represents a 
hydrophilic compound, whilst high LogP values are hydrophobic. We therefore can 
theorise the bioavailability of a drug and how successful it can be distributed amongst 
body compartments using LogP. LogP is particularly important in oral drug design 
as it aids ADME/PK modelling. Using LogP helps distinguish a drug’s ability to be 
absorbed in the gastrointestinal tract (GIT), to cross hydrophobic cell membranes and 
distribute in aqueous cytosol. This aids the modeling of its distribution across body 
and cellular compartments (Harris & Logan, 2014). LogP is also crucial in 
determining a drug’s lipophilic efficiency (LipE, eq.3), a critical parameter used to 
establish the quality of a drug in terms of potency (effectiveness of a drug to inhibit 
a specific biological function (IC50)) and toxicity (Eddershaw et al., 2000). Changes 
in LogP after drug alterations can be used to establish whether the modification is 
beneficial, as a reduction in LogP represents a decline in a drug’s toxicity (Hughes 
et al., 2008). Lipophilic drugs transfer readily into cells due to their increased 
membrane fluidity and permeability, therefore augmenting their metabolism (Kalepu 
et al., 2013). This enhancement in metabolism can lead to heightened action and thus 
increasing the prospect of drug toxicity. Therefore a drug with a high LipE and a low 
LogP can be deemed as a high quality clinical candidate (Freeman-Cook et al., 2013).    
Log7 = log	( Q$f:$`b? @p$q#^b$P
Q$f:$`b? 	r^#M_
)      à   (Equation 2) 
LipE = - log(IC50) – LogP                    à   (Equation 3) 
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The predicted LogP values for the kynurenine pathway analytes are all low, with 
QUIN being the most hydrophilic whilst KYNA is the most lipophilic. They are 
highlighted in Table 1.3.  
 
Table 1.3 – Partition Coefficients of Endogenous Kynurenine Metabolites (The Royal Society 










1.4  Summary of Introduction 
	
The kynurenine pathway is an important metabolic pathway in the regulation of 
inflammation in multiple disease states. KMO is a fundamental gateway enzyme that 
converts KYN into the cytotoxic metabolite 3HK. Current research by the Mole 
group, in collaboration with GlaxoSmithKline Plc, has established the importance of 
the metabolites of the kynurenine pathway in the progression of AP into AP-MODS 
and the subsequent poor patient outcomes. Consequently, a novel, potent inhibitor of 
KMO, GSK180, has been developed which prevents the progression of AP to AP-
MODS in rodents. KMO inhibition provides a novel approach to the therapeutic 
treatment strategies in systemic inflammation and thus could radically reduce 
























To investigate and determine the precise pharmacokinetics of the kynurenine 
pathway in the systemic circulation, with focus on the enzyme reaction rate of KMO. 
 
OBJECTIVE: 
To use stable isotope tracers, (13C6 or 2H) TRP, KYN, KYNA and 3HK to develop a 
metabolic model of TRP metabolism via the kynurenine pathway, identifying the 
exact rates of formation and elimination of each metabolite of interest, and the 
percentage of KYN used as substrate by KMO, and to determine the rate of 3HK 
formation. 
 
SECONDARY AIMS AND OBJECTIVES: 
Because two of the tracers (D5-KYNA and 13C6-3HK) in preliminary studies could 
not be detected and quantified in rat plasma using the protein precipitation and mass 
spectrometry methods previously used by the Mole group, an additional aim was to 
develop and validate a precise, sensitive, accurate and reliable laboratory assay that 
encompasses: 
• The extraction of all major kynurenine pathway metabolites from plasma.  
• Measurement of all major kynurenine pathway metabolites via liquid 
chromatography tandem mass spectrometry (LC-MS/MS) under one assay. 
o With a Limit of Quantification (LOQ) of 50 µg/L, or lower, for all 
metabolites. 
o Improved detection of D5-KYNA and 13C6-3HK at low plasma levels. 
o Calibration curves achieving excellent linearity (R2 > 0.99) and 
method validation in compliance with FDA guidelines. 
 
Lastly, the aim was to formulate a pharmacokinetic model of the kynurenine 
pathway. To achieve this, the data obtained, using the newly developed LC-MS/MS 
assay, for the rat plasma that had been intravenously (IV) infused with tracer will be 































This chapter describes the laboratory methods and apparatus that were used in the 
design and development of the experimental assay used in the analysis of plasma 
samples from rats that had been given a bolus IV injection of specific kynurenine 
pathway metabolite tracers.  
 
3.1  Materials 
 
3.1.1  Tracers  
	
All tracers were purchased in powdered form and suspended in high performance 
liquid chromatography (HPLC) grade water to produce the concentrations stated in 
Table 3.1. The concentrations of D5-TRP and 13C6-KYN used were formulated by 
identifying the endogenous levels found in rats and estimating a concentration of 
tracer that would represent 10% of these levels. Higher concentrations of D5-KYNA 
and 13C6-3HK were required to achieve suitable peak areas for quantifiable detection 
on the LC-MS/MS, in keeping with FDA guidelines. Therefore, the concentrations 
identified in Table 3.1 are the lowest achievable concentrations that enabled the 





















































Disposable Culture Tubes Borosilicate Glass (12x75 mm) Fisherbrand, 
Loughborough 
HiPerSolv grade Methanol (CH3OH) VWR Prolabo Chemicals, 
Leicestershire 
HPLC grade Water (H2O) 
Fisher Scientific UK, 
Loughborough 
Formic Acid Reagent Grade >95% 
Sigma Aldrich®, Dorset 
Phosphoric Acid Reagent Grade 85 wt. % in H2O 
Sigma Aldrich®, Dorset 
Finnpipettes F2 kit 4 Thermo Scientific, Cupar 
Pipette Tips volume range 10 µl -1 ml Thermo Scientific, Cupar 
Oasis® Hydrophilic Lipophilic Balanced (HLB) 96 well plate (10 mg 
Sorbent well, 30 µm Particle Size) 
Waters Limited, 
Hertfordshire 
Greiner Masterblock® 96-well collection plate Sigma Aldrich®, Dorset 
IST VacMaster™ 96-well vacuum manifold  Biotage®, Sweden 
Driblock DB3 Sample Concentrator Techne, Staffordshire 
Needles (76 mm long) Techne, Staffordshire 
SPE Dry™ 96 Dual Sample Concentrator System  
Microplate Sample Evaporation System for 96-well plates 
 
Biotage®, Sweden 
PV-1 Vortex Mixer Grant Instruments, 
Cambridgeshire 
KS 260 Basic Shaker IKA®, Germany 
4% Phosphoric Acid (H3PO4) in HPLC Grade water  
  
0.1% Formic Acid (CH2O2) in HPLC Grade water 
0.1% Formic Acid (CH2O2) in HPLC Grade water 





3.2  Methods 
	
3.2.1  Jugular Vein and Carotid Artery Cannulation in Rats Protocol 
	
The studies of the pharmacokinetics and pharmacodynamics of kynurenine pathway 
metabolite tracers were performed in rats (male, Sprague Dawley, body weight 250-
350g) obtained from Charles River Laboratories. Central vascular catheters, jugular 
vein and carotid artery, were placed under terminal anaesthesia (Isoflurane) (Mole et 
al., 2008). Rats were then dosed with predetermined optimised concentrations of 
tracer (see Table 3.1) via IV infusion (0.1 ml / 100 g) through the jugular vein. Blood 
samples (500 µl) were collected via the carotid artery 1 minute before IV infusion, 
then at 1, 5, 10, 15, 30, 60, 120, 180 minute intervals for D5-TRP and 13C6-KYN. For 
D5-KYNA and 13C6-3HK  blood was collected at 1, 3, 5, 8, 15, 30, 60 minute intervals 
due to their faster metabolism. Patency of the cannulae was maintained throughout 
the experiment by flushing with sterile saline (500 µl) after each sample was taken.  
The samples were then immediately aliquoted into ethylenediaminetetraacetic acid 
(EDTA) tubes, inverted and then subjected to centrifugation (3 mins, 5,000 RPM). 
The plasma supernatant was then aliquoted (100 µl) into three 1.25 ml eppendorfs 




3.2.2  Sample Extraction 
	
3.2.2.1  Stock Solutions and Standard Calibration Curve 
	
Individual stock solutions of each endogenous compound and tracer were prepared 
by dissolving in HPLC grade water and stored in a freezer (-20oC) (Table 3.2).  
 






























1 1 1 1 1 1 2 2 1 0.4 5 0.5 
 
Mixed-analyte master stocks (25 µg/mL concentrations) were then created by mixing 
the individual compounds together (Table 3.3). These were then serially diluted with 
methanol to create reference standard solution stocks (Table 3.4). All solutions were 
stored in a freezer at approximately -20oC prior to use.  
 
Table 3.3 – Master Stocks  (25 µg/ml) 















All Analytes 175 175 175 175 175 175 87.5 87.5 175 437.5 35 350 4778 
9 Analyte  
(D5-TRP) 
175 175 175 175 175 175 87.5 87.5 175 0 0 0 5600 
9 Analyte  
(13C6-KYN) 
175 175 175 175 175 175 87.5 87.5 0 437.5 0 0 5338 
9 Analyte  
(D5-KYNA) 
175 175 175 175 175 175 87.5 87.5 0 0 35 0 5770 
9 Analyte  
(13C6-3HK) 













Mix Stock used for 
dilution (µg/ml) 
Volume of Standard 




10 25 (Master  Stock) 2.8 4.2 
5 10 3.5 3.5 
2 5 2.8 4.2 
1 2 3.5 3.5 
0.5 1 3.5 3.5 
0.2 0.5 2.8 4.2 
0.1 0.2 3.5 3.5 
0.05 0.1 3.5 3.5 
0.02 0.05 2.8 4.2 
0.01 0.02 3.5 3.5 
 
The standard calibration curve consisted of one replicate of ten non-zero standards 
(Tables 3.5 and 3.6). Each calibration curve was prepared afresh on the day of sample 
extraction. All calibration curves were prepared by spiking 1% bovine serum albumin 
(BSA) in phosphate buffer solution (PBS), acting as a plasma matrix surrogate. The 
preparation of the standard calibration curves followed the exact same method as 
described in section 3.2.2.2. 
Table 3.5 – Base Template for Standard Calibration Curves that were 
Created Fresh each Experiment whilst Analysing Levels of Tracer in Rat 
Plasma. 





0 10 µl x 5 µg/ml 0 
0.1 10 µl x 5 µg/ml 10 µl x 0.01 µg/ml 
0.2 10 µl x 5 µg/ml 10 µl x 0.02 µg/ml 
0.5 10 µl x 5 µg/ml 10 µl x 0.05 µg/ml 
1 10 µl x 5 µg/ml 10 µl x 0.1 µg/ml  
2 10 µl x 5 µg/ml 10 µl x 0.2 µg/ml 
5 10 µl x 5 µg/ml 10 µl x 0.5 µg/ml 
10 10 µl x 5 µg/ml 10 µl x 1 µg/ml 
20 10 µl x 5 µg/ml 10 µl x 2 µg/ml 
50 10 µl x 5 µg/ml 10 µl x 5 µg/ml 
100 10 µl x 5 µg/ml 10 µl x 10 µg/ml 
39	
	
The base template for the calibration curves was adjusted and amended, depending 
on the tracer used, to maximise the number of points on the curve that lay within the 
range of tracer levels seen in the rat plasma. The internal standards used depended 
on the tracer analysed, D5-TRP was used when analysing 13C6-KYN, 13C6-3HK and 
D5-KYNA whilst 13C6-KYN was used when analysing D5-TRP. 
 
3.2.2.2  Rat Plasma Sample Extraction using Solid Phase 
Extraction 
	
This method describes the optimised protocol that developed throughout the study 
(Section 3.3)  
 
3.2.2.2.1  Preparation of Calibration Curve and Rat Plasma Before 
Administration to Waters Oasis® HLB 96-well plate.  
	
Plasma concentration of tracers and endogenous levels of kynurenine pathway 
metabolites were assessed using ultra-high performance liquid chromatography 
(UHPLC)-MS/MS. Plasma samples to be analysed were removed from -80oC freezer 
and thawed in ice. A borosilicate glass tube was labelled for every plasma sample 
and calibration curve point. Internal standard (50 ng) was then added to every tube 
along with the corresponding volume of standard analyte mix to the calibration curve 
tubes. These were then placed in a preheated Driblock (40oC) and evaporated to 
dryness. 100 µl of 4% phosphoric acid was then added to every tube and vortexed 
for ten seconds. 100 µl of rat plasma or 1% BSA was added to the corresponding 





3.2.2.2.2  Preparation of Waters Oasis® HLB 96-well Plate and 
Extraction of Rat Plasma.  
	
Methanol (500 µl) was added to extraction wells (Oasis® Hydrophilic Lipophilic 
Balanced (HLB) 96-well 10 mg sorbent well, 30 µg particle size) before subjection 
to vacuum (0.35 Bar) to dryness. To condition, HPLC grade water was then added to 
equilibrate wells and prime them for sample administration. Standards and internal-
standard-enriched samples (200 µl) were added. After incubation (RT, 5 mins) the 
HLB plate was then subjected to vacuum (0.35 Bar) to dryness. Wells were then 
washed with water (500 µl) and then vacuumed. A Masterblock® 96-well collection 
plate was then placed inside the vacuum manifold, 80% methanol (200 µl) added to 
HLB plate and extracts collected under vacuum. The eluates in the collection plate 
were then evaporated to dryness under oxygen-free nitrogen (OFN, 30 L/min, 60oC). 
Analytes were then resuspended in HPLC grade water (70 µl) before the plate was 
placed on a shaker (5 mins). Methanol was then added (30 µl) and the plate was 
shaken again (5 mins). Samples were then injected onto the HPLC-MS/MS system 
(10 µl). 
 
3.2.3  Instrumentation 
The UHPLC-MS/MS, for use in the analysis of the rat samples, was comprised of a 
Shimadzu Nexera MP UHPLC with an AB SCIEX QTRAP 6500+ triple quadrupole 
system mass spectrometer, operated by Analyst® software (SCIEX, Cheshire, UK). 
The column used for analysis was an ACE Excel UHPLC silica column comprised 
of a C18 bonded to pentafluorophenyl (PFP) phase (C18-PFP) (1.7 µm, 2.1 x 100 
mm, Advanced Chromatography Technologies Ltd., Aberdeen, Scotland). The 
sample was injected (10 µl); column oven temperature was 40oC. Two mobile phases 
were used 0.1% formic acid (Phase A) in water and 0.1% formic acid in methanol 
(Phase B) at a flow rate of 0.4 ml.min-1, compounds were eluted using the gradient 




Table 3.6 - Composition of Phases Being Pumped into LC-
MS/MS Throughout Run. 




0.00 10 90 
1.00 10 90 
6.00 80 20 
8.00 80 20 
8.10 10 90 
9.00 Stop 
Mass spectra were recorded using electrospray ionisation mass spectrometry (ESI) 
in both positive and negative multiple reaction monitoring (MRM) modes over a run 
time of nine minutes. The parent/product transitions (Q1àQ3, m/z) along with 
typical retention times for each analyte were optimised (See Section 4). Instrument 
control, data acquisition and integration were processed using Analyst® Software, 
Version 1.6.3 (SCIEX, Cheshire, UK). Data processing was performed using 
MultiQuant™ Software, Version 3.0.2 (SCIEX, Cheshire, UK).  All peaks were 
analysed individually and only accepted if they satisfied the criteria described in the 




3.3  Method Formulation and Validation 
	
In order to develop an optimised, enhanced and precise method of kynurenine 
pathway metabolite analysis, multiple experiments were undertaken to assess the 
following:  
 
3.3.1  Extraction Method 
	
Three main approaches to protein extraction were identified: protein precipitation 
(PPT), supported liquid extraction (SLE) and solid phase extraction (SPE). Plasma 
was enriched with a four tracer mix (100 ng). The recovery and ion suppression of 
each tracer analyte were used to compare these approaches.  
 
3.3.1.1  LC-MS/MS Method for Formulation  
	
During the method formulation, a different LC-MS/MS method was used due to 
availability of systems. This LC-MS/MS system comprised of a Waters ACQUITY 
UPLC® with an AB SCIEX QTRAP 5500. Samples were analysed by LC-MS/MS 
in MRM mode, by injecting 10 µl onto an XSelect High Strength Silica (HSS) PFP 
column (3 x 100 mm; 2.5 µm). Once the extraction method had been optimised, the 
LC-MS/MS analysis was transferred to the Shimadzu Nexera MP front end with an 
AB SCIEX QTRAP 6500+, injecting 25 µl onto the same column. This column was 
then compared with a different UHPLC column, an ACE Excel UHPLC (C18-PFP) 





3.3.1.2  Protein Precipitation 
	
Plasma was precipitated using a protein precipitation plate (Isolute® PPT+ 96-fixed 
well 1ml, Biotage, Sweden). Three solvents were tested; acetonitrile (300 µl), 
methanol (500 µl) or 1 M TCA (300 µl).  Samples were prepared in triplicate for 
each solvent.  Plasma (100 µl), was enriched (13C6-KYN, 13C6-3HK, D5-KYNA and 
D5-TRP, 100 ng) in a glass vial and the sample then transferred to the solvent 
prepared PPT+ 96-well plate.  The sample was left to stand in the wells (60 mins) 
and a vacuum was applied (3 mins, 0.35 Bar) to elute.  The solvent was dried down 
under OFN (60oC, 30 L/min) and resuspended in methanol and water (100 µl, 50:50, 
v/v). Non-enriched plasma (100 µl), was also subjected to protein precipitation and 
subsequently post-spiked with 13C6-KYN, 13C6-3HK, D5-KYNA and D5-TRP 
mixture (100 ng) at the time of resuspension in methanol in water (50:50, v/v), by 
adding a standard mixture in methanol (10 µl, 1 µg/ml), along with further methanol 
(40 µl) and water (50 µl).   
 
3.3.1.3  Supported Liquid Extraction  
	
Plasma was extracted using an SLE+ plate (Isolute® SLE+ 400 µl 96-fixed well, 
Biotage, Sweden). Standard tracer mix (100 ng) was added to water or plasma (100 
µl) in a borosilicate glass vial and diluted with water (1:1) before being transferred 
to the SLE+ plate. A solvent (methyl tert-butyl ether (MTBE), dichloromethane 
(DCM), hexane or diethylether, 1 ml), was added before being left to incubate (30 
mins). The solution was then pulled through by vacuum and dried down under OFN 
(60oC, 30 L/min) before being resuspended in methanol and water (100 µl, 50:50, 
v/v).  
 
3.3.1.4  Solid Phase Extraction 
	
Individual Oasis® HLB cartridges (10 mg sorbent, 30 µm particle size, Waters, USA)  
were used to extract plasma (100 µl) enriched with tracer standard mixture (100 ng).  
Each cartridge was conditioned with methanol (500 µl), equilibrated with water or 
4% phosphoric acid (500 µl), then the sample was loaded (100 µl) with a dilution 
solution (4% phosphoric acid or 5% ammonium hydroxide)  (100-400 µl). The 
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samples then underwent a first wash with water (500 µl), a second wash with another 
solvent (500 µl of 4% phosphoric acid or 5% methanol) and eluted with methanol (2 
x 250 µl). The eluent was dried down under OFN (60oC, 30L/min) and resuspended 
in methanol in water (100 µl, 50:50, v/v).  
Different volumes of solvent at the loading step were tested (100, 200, 300 and 400 
µl).   
 
3.3.1.5  Optimising Solid Phase Extraction Method 
	
The best results were achieved using the Oasis® HLB cartridges. The following 
method optimisation experiments were undertaken using the recommended protocol 
(Oasis® HLB, Waters, USA) as a construct (Figure 3.1) upon which to develop the 
ideal extraction protocol that enables all analytes to be extracted and analysed with 






(Figure 3.1 - Oasis® HLB Extraction Protocol (Waters, USA)) 
Priming of Sample  
Plasma samples were primed before administering onto columns using either an acid 
(4% phosphoric acid) or base (5% ammonium hydroxide) at a series of different 
dilutions (1:1, 1:2, 1:3, 1:4).  
Equilibration of Column 
Equilibration of columns was optimised by comparing the use of 4% phosphoric acid 
or HPLC grade water.  
Wash 1 and 2  
Washes were optimised by comparing the use of 5% methanol, water or 4% 
phosphoric acid. The number of post load washes were also compared.  
Elution 
The optimal elution solvent was assessed by comparing concentrations of methanol 
in water from 40% methanol to 100% in increments of 10%.  
Resuspension 
Premixed solutions of 50% and 70% methanol, along with individual additions of 




3.3.2  Chromatographic Conditions 
	
To achieve optimal peaks, multiple chromatographic conditions were assessed, these 
were: 
• LC-MS/MS apparatus 
o Two different LC-MS/MS systems were compared, a Shimadzu 
Nexera MP/ AB SCIEX QTRAP 6500+ triple quadrupole system and 
a Waters ACQUITY UPLC® / AB SCIEX QTRAP 5500 triple 
quadrupole system. The system that achieved superior peaks (peak 
shape and area) at low concentrations would then be used for analysis 
of rat plasma samples.  
• Column 
o Two different columns were then compared on the superior system, 
an ACE Excel UHPLC (C18-PFP) (1.7 µm, 2.1 x 100 mm) and a 
Waters XSelect HSS PFP column (3 x 100 mm; 2.5 µm) to identify 
which column produced superior peaks for 13C6-3HK and D5-KYNA 
(peak shape and area).  
• Flow rate 
o Different flow rates (400, 500, 600 µL/min) of mobile phase were 




3.3.3  Method Validation 
	
For the method validation to be satisfactory, the data had to satisfy the following 
FDA criteria: 
 
• The precision of the lowest acceptable standard on the calibration curve, the 
lowest limit of quantitation (LLOQ), around the mean value of a minimum of 
five out of 6 replicates must not exceed 20.0% relative standard deviation 
(RSD).  
• The precision of all other standards on the calibration curve around the mean 
value of a minimum of five out of six replicates must not exceed ±15% RSD.  
• The 1/x weighted linear regression correlation coefficient (R2) of standard 
concentration versus instrument response should be at least 0.99 for every 
assay validation batch.  
• A minimum of six standards on the calibration curve must fall within 
accuracy limits of ±20% at LLOQ and ±15% for all other standards. If there 
are insufficient numbers of standards that satisfy this criterium, the 
calibration curve should be re-evaluated using 1/x2 regression analysis.  
 
3.3.3.1  Recovery and Ion Suppression 
	
Replicates of four-tracer analyte mixes (13C6-KYN, 13C6-3HK, D5-KYNA and D5-
TRP, 100 ng) pre- or post-spiked in rat plasma (n=6) were compared to assess analyte 
recovery and ion suppression. Recovery was assessed by calculating the mean of the 
integrated peak areas of the extracted standards and displaying them as a percentage 
of the mean of the unextracted standards. Ion suppression was assessed by calculating 
the mean of peak areas of extracted samples and displaying them as a percentage of 




3.3.3.2  Extraction Efficiency 
	
The efficiency of the assay was measured by comparing the peak areas of seven 
kynurenine metabolite compounds (TRP, KYN, KYNA, 3HK, QUIN, AA, 3HAA), 
spiked in 1% BSA, in six standard curves across six separate days. Intra-day 
efficiency was also assessed by extracting and analysing six separate curves in the 
same day.  Precision and accuracy were calculated using the mean and relative 
standard deviation for each concentration on the curve.  
 
3.3.3.3  Optimisation of MS/MS Detector Parameters and Manual 
Tuning  
	
The MRM scan mode parameters (Q1àQ3) were calibrated using Analyst® 
Software in conjunction with the Shimadzu Nexera MP/ AB SCIEX QTRAP 6500+ 
triple quadrupole system.  
 
3.3.3.4  Dilution Linearity 
	
Replicates (n=6) of extracted control rat plasma, were diluted ten-, twenty-, fifty- 
and a hundred- times in methanol in water (30:70, v/v) then analysed on the UHPLC-




3.4  Pharmacokinetics Analysis of Data 
	
PK analysis of the data was performed using PKSolver 2.0, an add-in program for 
Microsoft Excel (Zhang et al., 2010). The entire data set for each tracer was originally 
inputted into Excel (time and concentration of tracer (µg/L)) and then transformed 
into a logarithmic scale to identify the first (distribution) and second (elimination) 
phases. The data points used for the elimination phase were then isolated and the 
gradient of the exponential line of best fit was identified (y = k-x). The initial 
concentration for the elimination phase for each tracer was established using two 
methods, firstly using the value of ‘k’ and then inputting the data points in Log10 
format into the ‘INTERCEPT’ function on Microsoft Excel. The Ci value was 
inputted into the PKSolver program (NCA IV Bolus formulation) along with the 






(Figure 3.2 - Development of PK analysis of D5-TRP Tracer Data Sets. A) 
Dissociation curve of D5-TRP. B) Logarithmic representation of D5-TRP 
dissociation C) Comparison of endogenous TRP with D5-TRP concentration levels. 




























4.1  Mass Spectrometric Conditions of Analytes and 
Examination of Peaks. 
	
The optimal LC-MS/MS conditions identified are detailed in Table 4.1. 
Table 4.1 – Optimised LC-MS/MS method for analysis of kynurenine pathway 
analytes. 
LC Settings   
System – Shimadzu / QTRAP 6500+  
Injection Volume: 10 µl 
Column: ACE Excel UHPLC C18 PFP 1.7 
µm 2.1 x 100 mm  
Column position:  
Mobile Phase A: H2O / 0.1% CH2O2 
Mobile Phase B: CH3OH / 0.1% CH2O2 
Flow Rate: 400 µL/min 






Initial 0.4 10 90 
1 0.4 10 90 
6 0.4 80 20 
8 0.4 80 20 


















10 / -10 
 
All analytes were ionised in both positive and negative ESI conditions. The MRM 
qualifier transitions (Q1àQ3) were identified by tuning each individual analyte (see 
Figure 4.1). Most analytes were ionised effectively in positive polarity, QUIN was 
negatively ionised. The final MRM transitions used in the final LC-MS/MS method 
are highlighted in Table 4.2. Representative chromatograms for each analyte, 










(Figure 4.1 - Identifying Analyte Transitions – A) Example of Q1 peaks in tuning 
using 13C6-3HK. B) Final fragmented analyte peaks C) representative chromatogram 
of extracted 13C6-3HK in 1% BSA (50 ng, m/z = mass to charge)
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(Figure 4.2 – Representative Chromatograms of Each Endogenous Analyte (100 ng).  Final quantifier transitions (m/z) are also 
displayed. Retention time of each analyte is displayed above corresponding peak. KYN chromatogram has a shadow peak from TRP 




(Figure 4.3 – Representative Chromatograms of Each Tracer (100 ng).  Final quantifier transitions (m/z) are also displayed. 




Table 4.2 – Parent/product molecular ion transitions (Q1àQ3, m/z) of all 
kynurenine pathway metabolites analysed using positive and negative ESI, 
along with their corresponding MRM mode settings (V, volts).  











KYN 209.0 192.2 61 11 10 
13C6-KYN 215.0 197.8 66 13 16 
TRP 205.1 188.1 36 15 12 
D5-TRP 210.0 192.1 60 15 6 
KYNA 189.9 144.1 46 23 10 
D5-KYNA 195.1 177.2 16 15 12 
3HK 225.0 208.0 56 11 32 
13C6-3HK 231.0 214.0 41 13 10 
3HAA 154.0 136.1 56 13 12 
AA 137.9 120.0 66 13 10 
XA 204.1 159.9 46 25 22 
negative 
QUIN 
165.9 122.1 -5 -14  -21 
 
 
4.2  UHPLC-MS/MS Method Optimisation 
 
The initial step in the development of the UHPLC-MS/MS methods was to select the 
most efficient and effective method of kynurenine pathway metabolite extraction. 
Three different methods of extraction (SPE, PPT and SLE) were assessed and their 
recovery and ion suppression outcomes compared. The method of extraction that 
provided the best recovery of analyte from the plasma samples was the SPE method 
using Oasis® HLB cartridges (Table 4.3, Figure 4.4). There was a stark contrast 
between the SPE method and the PPT and SLE methods, the percentage recovery of 











Table 4.3 - Comparison of Extraction Methods using Tracer Analyte 
Recovery from Plasma. (Optimal result highlighted in bold; Recovery = peak 
area of tracer extracted/peak area of tracer unextracted)  
Protein Precipitation  D5-TRP 13C6-KYN D5-KYNA 13C6-3HK 
MeCN  7.57% 7.34% 51.15% 2.57% 
CH3OH 6.44% 5.36% 51.39% 2.07% 
TCA  3.22% 8.10% 74.98% 2.58% 
 
Supported Liquid Extraction 
MTBE 1.44% 0.58% 0.01% 0.92% 
DCM 0.98% 0.86% 0.01% 0.42% 
Hexane 0.17% 0.81% 0.01% 0.26% 
EtOEt 1.07% 0.96% 0.01% 0.57% 
98:2 DCM/IPA 0.55% 0.41% 0.01% 0.43% 
EtOAc 1.57% 1.27% 0.01% 0.80% 
 
Solid Phase Extraction 
Acidified 1:1 HLB 79.22% 28.82% 92.50% 6.75% 
Acidified 1:2 HLB 67.16% 23.18% 93.79% 5.53% 
Acidified 1:3 HLB 39.74% 20.95% 95.92% 5.41% 
Acidified 1:4 HLB 76.04% 13.91% 97.97% 3.25% 
Base 1:1 HLB 16.43% 13.91% 3.70% 3.70% 
Base 1:2 HLB 18.59% 14.12% 2.47% 2.47% 
Base 1:3 HLB 22.10% 15.52% 2.15% 1.62% 





(Figure 4.4 – Statistical Comparison of SPE against PPT and SLE Methods of 
Extraction. The percentage recoveries, obtained by the acidified SPE method for each 
of the four tracers, were compared against the recoveries seen with samples extracted 
by PPT and SLE plates. The recoveries were significantly higher for every tracer. 
(Each tracer data set was subjected to a one-way ANOVA (p < 0.0001) with post hoc 
Tukey’s multiple comparisons test (* = p < 0.05; ** = p < 0.01; *** = p < 0.001 **** 





The next step was to optimise the Oasis® HLB extraction method, following the 
template provided by Waters but tweaking the steps to try and optimise recovery of 
13C6-3HK and D5-KYNA. Acidifying the plasma in 4% phosphoric acid (1:1, v/v) 
provided the best recovery results (Table 4.3), with the exception of D5-KYNA where 
a one in four dilution provided a 5.47% increase. The next steps in the cartridge 
preparation, equilibration and washing, were then further optimised (Table 4.4). By 
equilibrating and washing with HPLC grade water, analyte recovery was improved 
(D5-TRP, +11.74%; 13C6-KYN +78.87%; and 13C6-3HK, +78.76%).  
 
Table 4.4 - Comparison of Equilibration (1) and Wash (2) Steps using Recovery of 
Tracer Analytes.(Best result highlighted in bold)  
Recovery  D5-TRP 13C6-KYN D5-KYNA 13C6-3HK 
1) Water 
2) 5% CH3OH 
82.32% 61.37% 64.91% 24.79% 
1) 4% H3PO4 
2) 5% CH3OH 
46.62% 41.19% 85.02% 18.47% 
1) Water 
2) Water 
90.96% 107.15% 134.15% 85.51% 
1) 4% H3PO4  
2) Water 
82.35% 90.02% 94.33% 73.33% 
1) 4% H3PO4  
2) 4% H3PO4  
0.84% 69.82% 107.89% 11.42% 
 
The next step that was to assess the resuspension of analytes once dried down post-
elution.  
Table 4.5 - Comparison of Resuspension Elutions using Peak Areas of Tracers 
Spiked in Aqueous Solution. (%RSD = 100 x standard deviation/mean) 
Peak Areas   D5-TRP   13C6-KYN   D5-KYNA   13C6-3HK  
100 µl 50:50 (CH3OH:H2O) 34,383 2,935,667 21,233,333 651,433 
100 µl 30:70 (CH3OH:H2O) 986,600 3,185,000 25,440,000 525,267 
150 µl 50:50 (CH3OH:H2O)  619,005 2,284,500 18,745,000 370,000 
200 µl 50:50 (CH3OH:H2O) 1,986,000 1,094,500 12,955,000 106,750 
Relative Standard Deviation  
100 µl 50:50 (CH3OH:H2O) 80.35% 12.77% 11.35% 7.05% 
100 µl 30:70 (CH3OH:H2O) 92.16% 4.29% 12.52% 2.37% 
150 µl (50:50 CH3OH:H2O) 130.91% 3.06% 4.79% 7.99% 







The 30:70 solution was better for the recovery of 13C6-KYN and D5-KYNA, however 
50:50 was better for 13C6-3HK and D5-TRP at varying volumes. Due to the percentage 
relative standard deviation (%RSD) of D5-TRP being far higher than any other analyte 
(Table 4.5), it was hypothesised that there may be an issue with the resuspension step 
of the method. Due to the differing solubility of analytes in aqueous environments, 
LogP (Table 1.3), it was questioned whether all the analyte was being retained in the 
vial rather than dissolved in the resuspension solution. The differences in LogP may 
affect the ability of an analyte to solubilise in the resuspension solution and thus 
different concentrations of methanol, along with adding methanol and water 
separately, were investigated to identify whether a certain percentage aided 
resuspension and recovery of the analytes. Previously, a pre-mix of methanol in water 
(50:50, v/v) solution was used for resuspension. Two different compositions (50:50 or 
30:70, v/v) of the solution were compared. A premix was also compared against the 
individual addition of each component, followed by a vortex (3 s), to identify which 




Table 4.6 – Recovery (optimal highlighted in bold) and Relative Standard Deviations (optimal highlighted in bold) of Analytes in 
Different Resuspension Conditions (Av, Average) 
100 ng aqueous extracted 
analyte mix (n=2) 
KYN 13C6-
KYN 










50 64 38 34 26 27 10 10 38 12 31 
%RSD 
 
15 18 41 54 7 6 6 5 12 17 18 





100 125 89 84 46 49 19 18 58 21 61 
%RSD 
 
3 3 2 4 13 17 16 14 0 12 8 
30 CH3OH 




77 93 65 61 56 54 15 15 56 28 52 
%RSD 
 





84 97 68 64 58 58 16 16 59 42 56 
%RSD 
 
2 1 5 6 14 3 10 8 0 23 7 





80 97 65 62 62 60 17 17 55 34 55 
%RSD 
 
8 9 9 12 1 7 1 0 12 37 10 
50 CH3OH 
then 50 H2O 
Recovery (%) 
 
88 112 74 68 76 73 17 16 59 24 61 




Extracted samples (n=2) for each resuspension phase were analysed and compared for 
peak areas and %RSD. The preferred resuspension step of the protocol involved the 
addition of water (70 µl, 3 s vortex), followed by methanol (30 µl, 3 s vortex) as this 
achieved the highest level of recovery (61%), and a good level of precision (8% RSD) 
 
The last step to optimise was the elution step. To date all elutions were performed 
using methanol. However, as discussed, each analyte has a different LogP and thus 
using a more aqueous solvent may enhance the elution of hydrophilic analytes off the 
column. Different solution of methanol in water (40% methanol to 100% methanol in 
10% increments) were used to elute the standard samples (100 ng analyte mixes) 
(Table 4.7). The largest peak area values for three of the tracers were produced with 
an 80% methanol elution solvent.  
 
Table 4.7 – Results of the Elution Solvent Analysis. (Optimal result highlighted in 
bold; Ion Suppression = Peak Area of Tracer Extracted in Plasma/Peak Area of 
Tracer in Water) 
Ion Suppression  
% Methanol D5-TRP   13C6-KYN  D5-KYNA  13C6-3HK 
40 64.48% 101.45% 26.63% 31.46% 
50 70.89% 79.18% 64.37% 16.16% 
60 81.24% 93.84% 78.90% 26.35% 
70 81.69% 95.49% 83.02% 20.65% 
80 94.88% 117.17% 93.26% 24.00% 
90 65.51% 97.47% 83.31% 16.86% 
100 14.28% 80.11% 79.74% 17.90% 
Peak Areas 
40 8,603,500 5,239,500 15,505,000 632,000 
50 9,459,000 4,089,000 37,475,000 324,700 
60 10,840,000 4,846,500 45,930,000 529,350 
70 10,900,000 4,931,500 48,330,000 414,800 
80 12,660,000 6,051,500 54,290,000 482,200 
90 8,740,500 5,034,000 48,500,000 338,650 





Before rat plasma was analysed for tracer levels using this optimised method, the 
surrogate matrix for the standard curve was assessed. The average peak areas of each 
tracer (100 ng) were prepared in 4 different matrices (0.2%, 1%, 10% BSA and Human 
Plasma, Table 4.8) and compared. Overall, 1% BSA gave the most similar peak areas 
of analytes to plasma, therefore 1% BSA was adopted as the surrogate matrix for the 
preparation of the standard curves.   
 
Table 4.8 – Comparison of Peak Areas in Surrogate Matrices (BSA) with 
Human Plasma (100 ng in BSA / 100 ng in Human Plasma) 
Comparison with Human Plasma D5-TRP 13C6-KYN D5-KYNA 13C6-3HK 
10% BSA 155% 136% 113% 180% 
1% BSA 123% 111% 129% 137% 





4.3  UHPLC-MS/MS Method Validation 
	
4.3.1  Selectivity 
	
Selectivity was evaluated to identify whether the tracers and analytes could be isolated 
and quantified in the presence of other compounds found in the rat plasma matrix. To 
address this, the average chromatographical retention times of the tracers and analytes 
in rat plasma were compared against the average retention times in 1% BSA (n=7 
calibration curves) and are highlighted in Table 4.9. 
 
Table 4.9 – Comparison of Retention Times of Tracers and Analytes in Rat Plasma 
and 1% BSA Established in the Chromatograms.  
Analyte 1% BSA Retention Time (mins) Rat Plasma Retention Time (mins) 
TRP 3.41 ± 0.00 3.39 ± 0.78 
KYN 1.91 ± 0.00 1.91 ± 0.44 
KYNA 3.62 ± 0.00 3.63 ± 0.00 
3HK 1.11 ± 0.00 1.10 ± 0.25 
3HAA 2.78 ± 0.01 2.77 ± 0.02 
AA 4.26 ± 0.00 4.26 ± 0.01 
QUIN 0.96 ± 0.50 0.99 ± 0.02 
XA 3.50 ± 0.01 3.51 ± 0.01 
D5-TRP 3.47 ± 0.02 3.42 ± 0.01 
13C6-KYN 1.89 ± 0.01 1.91 ± 0.04 
D5-KYNA 3.67 ± 0.01 3.70 ± 0.01 





4.3.2  Dilution Linearity 
	
Due to saturation of the column while assessing endogenous plasma TRP levels, 
dilution linearity tests were performed to establish whether multiple dilution factors 
would produce the same, accurate and reliable results. The dilution linearity test was 
also used to assess the matrix suppression effect of rat plasma.  The results prove there 
is a good dilution linearity for TRP (dilution factor 10 – 100, R2 = 0.9938), therefore 
also identifying no severe matrix suppression effects (Figure 4.5). However, diluting 
samples by a factor of 100 produced a high relative standard deviation (32% RSD), 
therefore outside the optimal dilution range (1:10 to 1:50). Linearity analysis of all 






(Figure 4.5 – Linearity of TRP A) Actual dilution factor compared against proposed 
dilution factor gives good linearity (R2=0.9938) B) Corrected peak areas identifies 
good level of similarity in reported results across each dilution and also reveals 
saturation of column at dilution factor 1. C) Analysis of variation of results for each 




4.3.3  Precision and Accuracy 
	
In accordance with FDA guidelines, intra-day (six standard curves run on one day) 
and inter-day (six standard curves run on six different days) analysis of the standard 
curve precision and accuracy were performed and summarised in Table 4.10. At least 
five curves for each analyte were used in determining the method’s abilities to produce 
























TRP	 5	 5.6	 112	 0.4	 7	 5	 5.1	 102	 0.4	 8	
	 50	 53	 106	 5	 9	 50	 53.2	 106	 7.7	 14	
	 1000	 1064	 106	 111	 10	 1000	 1012.5	 101	 28.7	 3	
	 	 	 	 	 	 	 	 	 	 	
KYN	 10	 10	 100	 1.2	 12	 10	 9.8	 98	 1.4	 14	
	 100	 95.2	 95	 7.4	 8	 100	 104.4	 104	 8.3	 8	
	 1000	 1007	 101	 31.3	 3	 1000	 997.6	 100	 30.4	 3	
	 	 	 	 	 	 	 	 	 	 	
KYNA		 20	 19.3	 97	 1.9	 10	 5	 5	 100	 0.8	 16	
	 100	 99.2	 99	 8.5	 9	 100	 88.5	 88.5	 13.6	 15	
	 1000	 1029	 103	 23.5	 2	 1000	 997.4	 100	 42.6	 4	
	 	 	 	 	 	 	 	 	 	 	
3HK	 10	 10	 100	 0.8	 8	 10	 10.9	 109	 2.6	 24	
	 50	 47.1	 95	 6.2	 13	 50	 45.3	 91	 8.8	 19	
	 200	 195.5	 98	 11.1	 6	 200	 195.7	 98	 13.7	 7	
	 	 	 	 	 	 	 	 	 	 	
3HAA	 20	 21	 105	 1.4	 7	 50	 50.2	 100	 5.3	 10	
	 500	 499.5	 100	 37.3	 7	 500	 548.8	 110	 75.2	 14	
	 1000	 1002	 100	 26	 3	 1000	 1099.5	 110	 232	 21	
	 	 	 	 	 	 	 	 	 	 	
AA	 5	 4.9	 98	 0.9	 18	 10	 9.8	 98	 0.8	 8	
	 100	 92.7	 93	 9.2	 10	 100	 94.6	 95	 8.5	 9	
	 1000	 1024	 102	 143	 14	 1000	 1013.4	 101	 47.4	 5	
	 	 	 	 	 	 	 	 	 	 	
QUIN	 200	 195	 98	 34.7	 18	 100	 104.4	 104	 13.2	 13	
	 500	 475.8	 95	 59.4	 12	 500	 456.7	 91	 38.7	 8	









Linearity of the curves used in the validation study are summarised in Table 4.11. 
 
Table 4.11 - Summary of Calibration Curve Linearity (R2) and Weighting. 
Analyte R2 (Average) Weighting 
TRP 0.997481 1/x2 
KYN 0.998363 1/x2 
KYNA 0.993783 1/x  
3HK 0.997892 1/x2 
3HAA 0.998616 1/x 
AA 0.997144 1/x2 
QUIN 0.998255 1/x  
 
 
4.3.4  Limit of Quantification 
	
The analyte limits of quantitation, i.e. the lowest amount of analyte that produces a 
peak that is three times higher than background noise, are summarised in Table 4.12.  
 
Table 4.12 – Limit of Quantification (LOQ) and Upper (ULOD) Limits of 
Detection of Kynurenine Pathway Analytes. The LOQ represents the lowest 
quantifiable peak in the standard curve used for analysis of that specific analyte. 
Representative linear curve weighting and linearity (R2) are also displayed. 
Analyte LOQ (µg/L) 
(n=3) 
Signal to Noise Ratio 
at LOQ (n=3) 
ULOD (µg/L) 
TRP 0.01 27.7 1000 
KYN 0.03 3.7 1000 
KYNA 0.01 12.5 1000 
3HK 0.73 3.8 1000 
D5-TRP 1.00 12.5 2000 
13C6-KYN 1.67 3.6 1000 
D5-KYNA 0.40 3.9 1000 
13C6-3HK 20 5.6 1000 
3HAA 0.01 11 1000 
QUIN 50 7.6 1000 
AA 0.04 4.4 1000 





4.3.5  Comparison to Old Method  
	
To confirm whether this new method was an upgrade to the old method, peak areas of 
the four main kynurenine pathway analytes, along with 13C6-3HK and D5-KYNA, from 
both methods were compared and the results are shown in Figure 4.6. Peak 
characteristics of old, intermediate and new methods were also compared and are 
displayed in Figure 4.7. 
 
(Figure 4.6 – Statistical comparison between the oldest and final methods. These 
comparisons revealed a significant improvement in the sensitivity of the kynurenine 
pathway metabolites whilst visible improvement is seen in the sensitivity of 13C6-3HK 






(Figure 4.7 – Comparison of Peaks Throughout Method Design. Systematic guide of peak morphology throughout method 
development. The new method has resulted in increased peak heights with generalised narrowing of the peaks in comparison to the original 
method. This is seen prominently with D5-KYNA (Peak Heights – OLD = 9110, NEW = 1.6e6 cps; Peak Width – OLD >0.5 mins, NEW < 
0.3 mins) and 13C6-3HK (Peak Heights – OLD = 4000, NEW = 7.3e4 cps; Peaks represent 100 µg/L (10 ng) unless otherwise stated; cps = 
counts per second) 
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4.4 Method Application to Rat Tracer Studies 
	
The standard curves, using peak area ratios (analyte area / internal standard area) used 
to analyse the rats dosed with each tracer are represented in Figure 4.8. Further details 
of each linear curve are highlighted in Table 4.13.  
 
Table 4.13 – Data for Standard Curves Used in the Analysis of Tracer 
Concentrations in Rat Plasma 
Tracer Data  
Points Used 
Weighting R2 Value Equation 
D5-TRYP 6 1/x2 0.99588 y = 0.04236x + 0.01035 
13C6-KYN 6 1/x2 0.99667 y = 1.09324e5x + 18133.453 
D5-KYNA 7 1/x 0.99048 y = 0.17080x + -0.01082 






(Figure 4.8 – Standard Curves of Each Tracer Prepared in 1% BSA Used for Analysis. Data points accepted onto curve are represented with 
blue fill. Internal standard, 13C6-KYN (50 ng))
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The mean averages and standard deviations of the plasma concentrations of each tracer 
are summarised in Table 4.14 whilst their corresponding dissociation curves, 
logarithmic scales and their levels compared to endogenous compounds are shown in 
Figure 4.9. The plasma concentrations were calculated by reading the corresponding 
peak area ratio value off the standard curve, the same standard curve was used for 
every rat in that tracer experiment. The values of each tracer at time point ‘0’ were 
used as a value for background noise and were subtracted from all the following 
measured time point concentrations.  
 
Table 4.14 – Average Concentration of Tracers Decreasing Over Time, with 
Standard Deviations. All data has been ‘zeroed’ by subtracting the value at 
time point 0 from all other temporal values. 
 Average [D5-TRP] (µg/L) (n=3) Average [
13C6-KYN] (µg/L) (n=4) 
0 4.37 ± 0.85 1.4 ± 0.5   
1 1837.57 ± 356.84 98.78 ± 30.20  
5 1057.33 ± 80.46 35.78 ± 10.54  
10 506.87 ± 103.47 18.70 ± 6.32  
15 402.27 ± 41.75 16.35 ± 3.41  
30 232.70 ± 55.89 7.75 ± 2.51  
60 88.33 ± 30.15 5.25 ± 2.00  
120 26.63 ± 11.03 - 
 Average [D5-KYNA] (µg/L) (n=3) Average [
13C6-3HK] (µg/L) (n=3) 
              
0 
1.40 ± 0.66 51.13 ± 3.63 
1 21.30 ± 2.42 207.77 ± 48.47 
3 12.20 ± 5.37 112.77 ± 27.33 
5 7.37 ± 2.08 68.70 ± 34.20 
8 6.03 ± 2.72 58.10 ± 3.55 
15 2.87 ± 1.48 44.60 ± 7.37 
30 3.23 ± 4.05 20.57 ± 1.76 
60 0.40 ± 0 6.87 ± 3.40 
 
The data show that each tracer has two distinct phases, the distribution phase 
(reflecting on the movement of the tracer around the body and surrounding tissues) 
and the elimination phase. Doses of both D5-TRP and 13C6-KYN were sufficiently low 
enough to represent an initial plasma concentration of 10% of endogenous compound 
levels. The lowest achievable doses of D5-KYNA and 13C6-3HK corresponded with 
an initial plasma concentration that was 62% and 256% of their endogenous compound 





(Figure 4.9 – Representation of Data from Table 4.12, (means with s.d.). Each tracer has two identifiable phases in their decay, a 
distribution phase and an elimination phase. Doses of tracer are as close to 10% of endogenous as possible whilst staying in limits of detection.   
A) D5-TRP. B) 13C6-KYN. C) D5-KYNA. D) 13C6-3HK.)


















Dissociation Curve of D5-TRP (500 µg/kg) in Rats (n=3)
















Two Phase Decay of D5-TRP in Rats






















Comparison of D5-TRP vs Endogenous TRP in Rats (n=3)
D5-Tryptophan Endogenous 
Tryptophan 


















Dissociation Curve of 13C6-KYN (20 µg/kg) in Rats (n=4)


















Two Phase Decay of 13C6-KYN in Rats




















Comparison of 13C6-KYN vs Endogenous KYN in Rats (n=4)
13C6 Kynurenine
Endogenous Kynurenine















Dissociation Curve of D5-KYNA (1 µg/kg) in Rats (n=3)















Two-phase decay of D5-KYNA in Rats
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Dissociation Curve of 13C6-3HK (20 µg/kg)  in Rats (n=3)





















Two-Phase Decay of 13C6-3HK in Rats

























4.4.1  Pharmacokinetics of Tracers 
	
For the PK analysis, each rat was analysed individually using PK Solver, the data was 
then collated and summarised in Table 4.15. Average plasma concentrations of each 
tracer declined to undetectable levels, with the exception of D5-TRP, within the 
experimental period. Assessment of each tracer’s elimination phase revealed that 13C6-
KYN and D5-KYNA have the longest and shortest half-lives respectively (D5-TRP, 
27.08; 13C6-KYN, 29.12; D5-KYNA, 12.14; 13C6-3HK, 16.01 min) along with the 





Table 4.15 – PK Parameter Analysis of Each Tracer. 
 PK Parameter 
  D5-TRP 13C6-KYN D5-KYNA 13C6-3HK 
Units Range Mean ± SD  Range Mean  ±  SD  Range Mean  ±  SD  Range 
Mean  ±  
SD  
Weight  g 320-325 323.33 ± 2.89 310-340 318.75 ± 14.36     315-340 330 ± 13.23 
Dose µg/kg 500   20   1   20   
Half Life (t1/2)  min 23.20-31.44 27.08 ± 4.14 
18.914-


















Initial Concentration (Ci)  µg/L 
540.42-
598.03 563.55 ± 30.44 
13.95-





Volume of Distribution (Vd)  
(µg/kg)/(µg/
L) 0.78-1.09 0.92 ± 0.16 0.67-1.23 0.96 ± 0.25 0.06-0.20 0.12 ± 0.07 0.14-0.28 0.21 ± 0.07 











Area Under Curve (AUC0-t)   
18068-
24658 20607 ± 3546 625-840 668 ± 145 118-139 131 ± 11 1747-2717 2072 ± 568 
Total Endogenous Levels of 
compound µg/L   19189.14   816.92   34.49   81.26 
Formation/ Elimination Rate of 
compound (µg/L)/min   
498.28 (total TRP) 
49.89 (estimated free 
TRP) 
 




























The kynurenine pathway is the primary systemic route of TRP metabolism. It is a 
biological process that plays a fundamental role in health and in the pathology of 
multiple disease states. These range from neurological disorders, for instance 
Huntington’s disease (Thevandavakkam et al. 2010) and Parkinson’s disease (Okuda 
et al. 1998); to ageing, irritable bowel syndrome (Majewski et al., 2016), systemic 
inflammation and multi organ dysfunction syndrome (Mole et al. 2016). Despite the 
importance of the kynurenine pathway in disease, the flux of the pathway has 
previously not been defined. This project therefore aimed to accurately define the rate 
of formation for TRP, KYN, KYNA and 3HK in health. The work presented in this 
dissertation details the exact pharmacokinetic parameters for each of the four 
metabolites studied. The enzymatic rates, in health, have been determined for KMO, 
KYNU and the collaborative rates of IDO and TDO. To make this possible, a new LC-
MS/MS analytical method, combined with a new extraction method, has been 
developed, enabling analyte concentrations as low as 0.01 µg/L to be accurately 
quantified, signifying this assay as one of the most sensitive assays for kynurenine 
metabolite analysis currently available.  
  
Prior to this body of work, the Mole group extracted kynurenine pathway analytes 
from plasma samples using a trichloroacetic acid (TCA) protein precipitation assay. 
This previous extraction analysis assay was optimised for the investigation of 
endogenous analytes in plasma and not for the tracers. Therefore it was not suitable 
for the analysis of D5-KYNA and 13C6-3HK tracers. Therefore a new assay was 
developed and optimised, from extraction to LC-MS/MS analysis, to address these 
issues. This culminated in a robust, reliable method used to analyse tracer-infused rat 
plasma.  
 
The initial experiments to detect these tracers at low levels with the old assay, 
produced erratic, wide and low intensity peaks. This lead to erratic standard curves 
and subsequent unreliability in quantification. Two leading factors to these issues were 
the large margin for human error during sample preparation and the low sensitivity to 
these tracers. Therefore, it was difficult to obtain suitable recovery of D5-KYNA and 
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13C6-3HK tracers as well as their endogenous counterparts at low concentrations and 
consequently difficulty in identifying quantifiable peaks in rat plasma suitable for the 
pharmacokinetic modelling of the kynurenine pathway.  
Because of this, the assay was redeveloped starting from analyte extraction from 
samples. The most common method of extraction used in LC-MS/MS studies of 
kynurenine pathway metabolites is PPT (Huang et al., 2013; Liu et al., 2011; Ohashi 
et al., 2013; Yamada et al., 2008), whilst SPE has also been used (de Jong et al., 2009; 
Möller et al., 2012). To identify the optimal method of extraction, three commonly 
used types of purposely made extraction cartridges/plates; PPT, SLE and SPE, were 
compared. Analyte recovery of the tracers from each method was used as a tool to 
compare and identify the superior extraction process. SPE produced superior analyte 
recovery compared to the other two methods (Table 4.3). With D5-KYNA and 13C6-
3HK being the two hardest tracers to detect at low levels, the selection of the extraction 
method was driven by results for these two tracers. The impact of phospholipids co-
eluting and being present in the final sample to be ionised in the LC-MS/MS can be a 
complication in analysis. Phospholipids contribute to the ‘matrix effect’ whereby the 
plasma matrix causes ion suppression leading to a decline in the sensitivity and 
precision of the LC-MS/MS (Ahmad et al., 2012). The Oasis® HLB cartridges limit 
the amount of phospholipids being eluted, thus cleaning the samples and reducing the 
ion suppression effects of the plasma matrix. The SLE plate also removes 
phospholipids from the sample. However, the analytes may not have adhered to the 
column and therefore could have been lost in the extraction process. These results led 
to the SPE method being chosen as the base template for further method design and 
optimisation. Multiple elements of the pre-determined Oasis® HLB extraction process 
were then addressed and optimised for kynurenine pathway compound analysis. These 
included the agents and volumes used in the acidification of the sample; conditioning, 
equilibration and washing of extraction cartridges or wells; eluting and resuspension 
of the samples. For example, during resuspension, adding 70 µL of water, vortexing, 
and then adding 30 µL of methanol before vortexing again improved recovery of all 
analytes (Table 4.6) when compared to using a premix or adding methanol first. Thus, 
this sequence of resuspension in sample preparation was adopted. The final method 








The old method and intermediate method 1 peaks seen in Figure 4.7 are examples of 
the marked difference the SPE extraction method had on the resolution and sensitivity 
of the analytes, with every analyte having enhanced peaks. The improvements seen in 
the peaks of KYNA, D5-TRP and D5-KYNA are particularly superior in comparison 
with the PPT extraction method. 
 
Because tracer levels in rats were being analysed, the purpose of this work was to 
develop an optimised single-run assay that could analyse all kynurenine pathway 
analytes and tracers from one plasma sample. With the newly developed assay, this 
can be accomplished. Analysing the majority of endogenous tryptophan metabolites, 
in one run, has been achieved before (Fuertig et al., 2016b; Möller et al., 2012). Other 
groups have focused on a select group of analytes (Huang et al., 2013; Orsatti et al., 
2015; Zhen et al., 2011) (Table 5.1).  
 
To be confident that the developed assay was reliable and robust, the target set was to 
achieve symmetrical and sharp peaks that would be easily quantifiable. This would 
enable the accurate identification of the PK parameters of each analyte. As low as 
81	
	
possible LOQs were sought, to permit the use of low doses of tracer, that equate to 
10% of endogenous levels, which would still be detected on the LC-MS/MS system. 
Doses equating to 10% of endogenous levels were chosen as the ideal target so as not 
to risk enzyme saturation and the potential of altering the flux of the kynurenine 
pathway (Uings, personal communication, 2016). To achieve this, the new assay 
would need to produce peaks of enhanced sensitivity and quality that could be 
quantified and used with confidence for PK analysis.  
 
Because there was difficulty in detecting low plasma concentration levels of D5-
KYNA and 13C6-3HK levels with the old method, the key peak characteristics that this 
project aimed to improve were height, an indicator of sensitivity to the analyte, and 
width, a marker of assay resolution and precision. An improved peak height, whilst 
reducing the noise, would improve the signal to noise ratio (S/N) and provide reliable 
and accurate peak areas for quantitation. Both sensitivity and resolution were 
improved by upgrading the LC-MS/MS system and applying a new UHPLC column 
respectively.  
 
The LC-MS/MS was upgraded to a Shimadzu Nexera MP LC tandem AB SCIEX 
QTRAP 6500+ system. The new system had similar sensitivity and resolution for the 
majority of analytes, with the exception of 13C6-3HK where there was a great 
improvement in peak heights and areas when compared with the intermediate method. 
Using this system, different columns, along with changing flow rates, were then 
compared to alter the resolution and identify the conditions that achieved peaks, in the 
biological samples, that were adequately separated, had excellent peak areas and were 
quantifiable, thereby producing reliable and accurate data that could then be utilised 
in PK analysis. Two columns were used. The ACE Excel UHPLC (C18-PFP, 1.7 µm, 
2 x 100 mm) column provided larger and sharper peaks across all concentrations in 
comparison to the Waters XSelect HSS PFP column (3 x 100 mm; 2.5 µm) whilst also 
reducing run times from eleven minutes to nine minutes. By reducing the particle size 
of the column (2.5 µm to 1.7 µm), the theoretical number of plates inside the column 
is increased (Van Deemter Equation), enabling more analyte to adhere to the column 
before being eluted. Figure 4.7 demonstrates the impact the reduced particle size had 
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on the resolution of the tracer peaks. Although using the Waters column on the new 
system provided greater sensitivity, shown as greater peak heights, the resolution was 
inferior to the ACE column. The characteristics of the 3HK, KYNA and their 
respective peaks seen using the Waters column were too wide and difficult to quantify 
due to hesitancy on which area of the peak truly represented the analyte. Therefore, 
the ACE column was chosen despite its lower sensitivity, due to the crispness of the 
peaks and subsequently enhancing the reliability and precision of the assay.  However, 
there was one limitation to the assay, the column was easily saturated at concentrations 
above 1,000 µg/L. This was an issue as endogenous levels of TRP are higher than the 
level of saturation, therefore a dilution analysis (1:10 – 1:100) was carried out to assess 
whether there was linearity across dilutions and therefore reliability in the data from 
diluted samples. Figure 4.5 highlights the results of the dilution experiment and shows 
that there is a good linearity across the dilutions with RSDs acceptable between 1:10 
– 1:50 dilutions, therefore samples would be diluted fifty-fold when analysing 
endogenous TRP levels.  
Conditions such as flow rates and compositions of mobile phase were altered for each 
column in an effort to achieve optimal conditions. The optimal flow rate for the ACE 
column was 0.4 ml/min and the varying compositions of mobile phase over time, along 
with all other conditions for the LC and MS components, are highlighted in Table 4.1. 
The analyte transitions were optimised using MRM scan mode parameters and the 
transitions that yielded the best peaks were incorporated into the MS method (See 
Figure 4.1 and Table 4.2). The highest sensitivity for TRP, KYN, KYNA, 3HK, AA, 
XA and 3HAA was seen using positive ionization whilst the highest sensitivity for 
QUIN was seen in negative ionization. These findings were mostly in agreement with 
those reported previously. However, in the literature there are differences in the 
ionization for QUIN and XA. Fuertig et al. report having better sensitivity if they are 
positively ionised (Fuertig et al., 2016a), whilst Möller et al. report they have better 
sensitivity if they are negatively ionised (Möller et al., 2012). Unfortunately, XA was 
unable to be separated entirely from TRP and therefore cannot be confidently 
quantified. Thus, future studies will need to optimise conditions further to be able to 




Once the assay had been finalised, the robustness, reliability and accuracy were 
investigated, according to the guidelines set out by the FDA. The method was 
subjected to a variety of different tests, described in Section 3. The intra- and inter-
day studies of precision and accuracy revealed that the system was reliable, precise 
and produced accurate levels of each analyte (measured by %RSD) ranging from 
concentrations representing levels lower than seen in plasma, to high standard 
concentrations (within-day  2-18 %RSD; between-day 3-15 %RSD). The range of each 
analyte standard curve encompassed the natural range of endogenous analyte seen in 
rat plasma samples, with the exception of TRP, which needs to be diluted as previously 
described.  
 
A secondary aim of this study was to lower the LOQs for each analyte. Experiments 
were performed, using low concentrations of analyte mixes (0.01 – 0.2 µg/L; n=3) to 
identify the sensitivity of the assay. The LOQs established in this assay compare 
favourably with those established by other groups (Table 5.2). Each analyte, with the 
exception of QUIN, has a lower LOQ, using the assay described, than any of the 
previous reports. The signal to noise ratios of TRP, KYNA and 3HAA also suggest 
that the assay may detect these analytes at even lower concentrations (Table 4.12). The 
assay differs from all the previously reported HPLC methods (Table 5.1) and 
represents the first use of UHPLC for the analysis of the kynurenine pathway. Fuertig 
et al. were able to produce the lowest LOQs from the literature previously reported. 
However, these were produced in aqueous solvent, thus there was no matrix to have 
an effect on the signal to noise ratio. This dissertation has provided LOQs that have 
been produced from samples where analyte has been spiked into a 1% bovine serum 
albumin and 4% phosphoric acid solvent. The work described in Section 4 (Table 4.8) 
has proved that this matrix environment is the best plasma surrogate matrix for the 
standard curves. Therefore, this assay may be one of the most sensitive assays for 





















Column Mass Spec Flow Rate 
(mL/min) 
R2 > 
De Jong et al. 2009 on-line SPE 250 300 50 8 HPLC Atlantis dC18 (100 x 
2.1 mm; 3µm) 
Micromass Quattro 
Premier with Z Spray  
0.05 0.99 
Zhen et al. 2011 PPT 100 N/A 25 8 HPLC BDS-Hypersil-C8 
(150mm x 4.6 mm; 5 
µm) 
not reported 0.6 0.99 
Moller et al. 2012 SPE 800 150 10 12 HPLC Restek C18 Aqueous 
100 x 2.1 mm 
API 2000 Triple 
Quadrople (ESI, SIR) 
0.2 0.95 
Huang et al. 2013 PPT 100 N/A 5 4.5 HPLC Synergi Polar RP (75 
x 4.6 mm) 
Micromass Quattro 
Ultima Triple 
Quadrople (ESI, SRM) 
1 0.99 
Orsatti et al. 2015 PPT 50 Not reported 10 4.3 HPLC Atlantis dC18 (2.1 





Fuertig et al. 2016 PPT / 
Ultrafiltration 
10 40-50 20 5.5 HPLC GRACE VisionHT 





Murray et al. 2016 SPE 100 100 10 9.1 UHPLC ACE Excel C18-PFP 
(2.1 x 100 mm; 1.7 
µm) 
















Table 5.2 - Comparison of Limits of Quantification (This project highlighted in bold) 
  Limit of Quantification (µg/L) 
Group Matrix TRP KYN KYNA 3HK 3HAA AA QUIN XA 
De Jong et al. 2009  Pooled Plasma 22.48 10.41 N/A 5.16 N/A N/A N/A N/A 
Zhen et al. 2011 Plasma 811 88 N/A 0.98 N/A N/A N/A N/A 
Moller et al. 2012 Plasma 7.2 7.3 10.0 N/A 12.9 6.4 336.6 N/A 
Huang et al. 2013 Water 1250 62.5 N/A N/A N/A N/A N/A N/A 
Orsatti et al. 2015 Water/acetonitrile (9/1) w 0.1% 
formic acid 
N/A 9.8 0.49 0.098 N/A 0.49 N/A N/A 
Fuertig et al. 2016 Acidified mobile phase 0.51 0.10 0.07 0.17 0.15 N/A 0.42 0.05 




Having solved the issues of producing symmetrical, quantifiable and reliable peaks for 
both 13C6-3HK and D5-KYNA (Figure 4.7), tracer-infused rat plasma samples were 
extracted and analysed using the method. The sensitivity of the method resulted in 
initial concentrations of D5-TRP and 13C6-KYN to be 10% of endogenous levels, 
whilst the initial concentrations of D5-KYNA and 13C6-3HK represented the lowest 
initial concentrations that provided us with quantifiable peaks throughout the duration 
of the experiment.  
In the analysis, standard curves that were used were linear and had an excellent line of 
best fit (R2 > 0.99). The data points included in these curves reflected the range of 
tracer levels seen in the samples (Figure 4.8). For D5-TRP and 13C6-KYN, the 
sensitivity of the system was sufficient to be able to infuse doses of tracer that were 
representative of 10% of endogenous levels, so not to disturb the flux of the pathway 
and risk saturating KMO and IDO respectively. For D5-KYNA and 13C6-3HK, this low 
level of detection could not be achieved, thus doses of tracer that were used represented 
the lowest dose that would achieve quantifiable levels of tracer throughout the 
experiment (D5-KYNA, 62%; 13C6-3HK, 256% of endogenous levels; Figure 4.9).  
Because a sufficient number of peaks were able to be quantified throughout the 
duration of each experiment, the pharmacokinetic model of the kynurenine pathway 
was defined. The enzymatic turnover for KMO in health has now been described along 
with the half-life, volume of distribution and elimination constants for each metabolite 
of interest. 
The data produced illustrates the two-phase decay of each tracer. The first phase 
representing each tracer being distributed into tissues rapidly. The second phase 
representing the elimination of the tracer from the plasma. Using this elimination 
phase, the PK parameters for each tracer (Table 4.15) were formulated. Thus, the PK 
of their corresponding kynurenine pathway compound was predicted. Each compound 
has a short half-life (D5-TRP 27.08 ± 4.14; 13C6-KYN 29.12 ± 7.51; D5-KYNA 12.14 
± 5.52; 13C6-3HK 16.01 ± 4.43; mins) highlighting the rapid flux of the pathway. 
Secondly, all tracers have a low Vd, with 13C6-KYN having the highest (0.96 ± 0.25 
(µg/kg)/(µg/L)) and D5-KYNA having the lowest (0.12 ± 0.07 (µg/kg)/(µg/L)). These 
differences in the Vd may aid the understanding of the reasons as to why there are 




(Figure 5.2. The Predicted Flux of the Kynurenine Pathway. It is predicted that of 
the circa 500 µg/L min-1 of TRP that enters and is eliminated from the blood circulation 
system during basal metabolic conditions, only 4.1% of this (20.73 µg/L min-1) is 
converted into KYN. Around 90% of the TRP will be bound to protein (circa 448.39 
µg/L min-1), leaving 29.1 µg/L min-1of free TRP to be eliminated via other 
mechanisms such as the production of serotonin, distribution into tissue and urinary 
excretion. 28% of the produced KYN is converted into either KA or 3HK, with the 
remaining 72% likely to be protein bound, metabolised into AA, distributed into 
tissues or excreted. Green boxes indicate progression down the kynurenine pathway. 
Values indicate the rate of formation/elimination of the compound. Blue boxes 






The relatively high Vd of TRP and KYN compared to 3HK and KYNA implies that 
the marked difference between formation/elimination rates across the metabolites 
could be due to high distribution of TRP and KYN into the surrounding tissues, or, be 
due to high levels binding to protein in the plasma, and therefore being absorbed into 
their corresponding reserve pool. It is known that 90% of TRP is protein bound in the 
plasma (Salter et al., 1989). As the assay measured total plasma levels of TRP, 90% 
of the TRP detected would have been bound to protein, therefore the remaining 10% 
(49.83 µg/L min-1) is the proportion of TRP that is subjected to metabolism and further 
tissue distribution.  PK analysis identified that 42% of free TRP is converted into 
KYN. KYN has been implicated in the competitive dissociation of TRP from albumin 
in the blood (Cangiano et al., 1999), thus the disparity between the elimination of KYN 
and the formation of KYNA and 3HK is likely to be due to KYN becoming protein 
bound or being eliminated via urinary excretion, reported to be twenty-five µg per day 
in rats (Saito et al., 2000). Another reason for these disparities along the kynurenine 
pathway could be due to the Vd and the ability for tissue distribution. TRP and KYN 
have a higher Vd than KYNA and 3HK. Thus, a larger amount of TRP and KYN will 
be distributed into cells, most notably the liver and kidneys where they are then 
metabolised. Thus this exodus of TRP and KYN into the tissue contributes to the 
elimination of these compounds from the plasma. The low Vd of 3HK and KYNA 
highlights the fact that these compounds prefer a hydrophilic environment and thus 
stay in the blood. This is further indicated with the varying levels of clearance from 
the plasma for each metabolite, where clearance is comparably high for TRP and KYN 
(0.024 ± 0.004 and 0.024 ± 0.005 µg/L min-1 respectively) and low for KYNA and 
3HK (0.007 ± 0.001 and 0.009 ± 0.002 µg/L min-1 respectively). Interestingly, the 
elimination constants for KYNA and 3HK (0.064 ± 0.023 and 0.045 ± 0.011 L/min 
respectively) were treble and double, respectively, the rates seen for TRP and KYN 
(0.026 ± 0.004 and 0.025 ± 0.008 L/min respectively). Thus, if KYNA and 3HK are 
being removed from the body at a higher rate than TRP and KYN, yet their 
formation/elimination rates in plasma are radically lower, then it must be the abilities 





This study successfully detailed the pharmacokinetics of four kynurenine pathway 
metabolites due to the development of a highly sensitive, reliable and robust LC-
MS/MS assay. The strengths of this study include the method of tracer administration. 
The use of indwelling vascular cannulae guarantees an exact dose of tracer. Cannulae 
also allow for accurate and timely retrieval of plasma from the rats, maximising the 
precision of the data obtained.  
The strengths of the LC-MS/MS assay include a low injection volume, therefore 
samples can be stored and analysed at a future date if needed. The low LOQs of the 
analytes culminated in an assay that can identify low levels of endogenous analytes 
with confidence. The low LOQs for D5-TRP and 13C6-KYN also facilitated the 
administration of these tracers at doses that equated to ten per cent of levels of their 
endogenous counterparts. The assay is robust and reliable, therefore the data obtained 
can be interpreted with confidence, culminating in a pharmacokinetic model that is 
precise. This pharmacokinetic model of the kynurenine pathway has defined the 
precise enzymatic rates of KMO and the enzymes upstream along with detailing the 
precise pharmacokinetic parameters for each analyte of interest.   
 
There are aspects of this project that could be improved with further development. The 
relatively high LOQs of D5-KYNA and 13C6-3HK, in comparison to their endogenous 
counterparts, prevented the study from achieving a dose that was equal to ten per cent 
of endogenous KYNA or 3HK. These high doses mean that the flux of the kynurenine 
pathway may have been altered, therefore there is potential that the precision of the 
PK data may have been affected. The fate of each analyte has also not yet been 
accounted for, with tissue and urine still to be examined. The downstream kynurenine 
metabolites have also not yet been analysed, therefore the flux of the entire kynurenine 
pathway is still to be defined.  
Finally, the large volume of plasma (100 µl) used for the initial SPE extraction 
accounts for up to 50% of the plasma retrieved for each time point. Therefore, the 







To address these issues, there are multiple experiments that can be done in future 
studies. To identify the precise distribution, metabolism and excretion of each analyte, 
analysis of urine collected from the tracer studies should be carried out. This will 
identify the quantities of tracer and the endogenous compounds that are not 
metabolised in the kynurenine pathway and are excreted through the urine. Proportions 
of the formation/elimination rate attributed to urine excretion can then be formulated.  
Levels of these analytes should also be identified in the tissues. Data from this study 
highlight marked differences in the Vd of each metabolite and the fate of each 
metabolite has yet to be fully defined. There are significant differences in their 
formation/elimination rates at each stage of the pathway. The analysis of different 
tissues will also aid the anatomical definition of the kynurenine pathway, detailing the 
exact locations of metabolite accumulation.    
The tracer experiments can also be used to identify the impact that KMO inhibition 
has on the flux through the pathway. Therefore these experiments could be repeated 
using a KMO inhibitor in rats, as well as using genetically altered KMO knockout 
mice, to identify the precise changes of metabolite levels upstream and downstream of 
KMO. These would identify the alterations in the pharmacokinetic model of the 
kynurenine pathway under conditions of absent KMO activity.  
Finally, further work into the optimisation of the LC-MS/MS assay should be carried 
out to reduce plasma volumes needed and to increase the sensitivity to D5-KYNA and 






5.2  Conclusion 
	
To conclude, the aim of this dissertation was to describe the flux of the kynurenine 
pathway, focusing on the enzyme reaction rate of KMO and the enzymes upstream. 
To identify these parameters, a new, single-run assay was developed for the 
identification and quantification of kynurenine pathway metabolites in rat plasma. 
This assay is capable of detecting and quantifying kynurenine pathway metabolites at 
concentrations as low as 0.01 µg/l, highlighting its excellent sensitivity.  
The PK of four of these metabolites (TRP, KYN, KYNA and 3HK) have been assessed 
and described, highlighting the variation in distribution and subsequent abilities to 
distribute into surrounding tissue. Consequently, the enzymatic reaction rates, in the 
healthy physiological state, were formulated. KMO has a basal reaction rate of 3.68 
µg/l min-1, the combination of  TDO and IDO generates KYN at 20.73 µg/l min-1 and 
KYNU yields KYNA at 2.21 µg/l min-1. Further work investigating the alterations to 
these rates, using both KMO inhibitors and mouse models of KMO knockouts are 
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